Method for producing cell population containing mesenchymal stem cells, mesenchymal stem cells, cell population, and pharmaceutical composition
By stimulating mesenchymal stem cells to enhance CD106-negative cells with metallothionein expression and applying freeze-thaw techniques, the method addresses the challenge of producing large quantities of mesenchymal stem cells with high proliferation rates, enhancing cell preparation efficiency.
Patent Information
- Application Number
- JP2022027560
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2015-10-27
- Filing Date
- 2022-02-25
- Publication Date
- 2024-11-14
- Estimated Expiration
- 2036-10-27
AI Technical Summary
Existing methods fail to efficiently produce large quantities of mesenchymal stem cells with high specific proliferation rates, which are crucial for rapid cell preparation in cell therapy applications.
A method involving physical or chemical stimulation to selectively enhance the proliferation rate of mesenchymal stem cells by identifying and increasing the proportion of CD106-negative cells with elevated metallothionein family gene expression, followed by freezing and thawing processes to enhance proliferation and resistance.
This approach allows for the rapid production of large quantities of mesenchymal stem cells with high specific proliferation rates, improving freeze-thaw resistance and enabling efficient cell preparations.
Smart Images

Figure 0007583413000005 
Figure 0007583413000006 
Figure 0007583413000007
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for producing a cell population containing mesenchymal stem cells (MSCs), the method comprising preparing mesenchymal stem cells (MSCs) suitable for cell therapy applications.The present invention further relates to mesenchymal stem cells, cell populations containing mesenchymal stem cells (mesenchymal stem cell populations), and pharmaceutical compositions containing said mesenchymal stem cells or said cell populations. [Background technology]
[0002] Mesenchymal stem cells, also known as mesenchymal stromal cells, are somatic stem cells that have been reported to exist in bone marrow, adipose tissue, etc., and have the ability to differentiate into bone, cartilage, fat, etc. Mesenchymal stem cells have attracted attention as a promising cell source in cell therapy, and it has recently been revealed that they are also present in fetal appendages such as the placenta, umbilical cord, and fetal membrane.
[0003] Mesenchymal stem cells have attracted attention for their immunosuppressive ability in addition to their differentiation ability, and the practical application of bone marrow mesenchymal stem cells for acute graft-versus-host disease (GVHD) and Crohn's disease, an inflammatory bowel disease, is progressing. Various cells are known as mesenchymal stem cells, and among them, amniotic mesenchymal stem cells have a high immunosuppressive effect and the amniotic membrane, which is the cell source, can be collected non-invasively, so that they are expected to be applied to cell therapy targeting various immune-related diseases (Patent Document 1).
[0004] Patent Document 1 describes a method for producing an amniotic mesenchymal cell composition, a cryopreservation method, and a therapeutic agent. Patent Document 2 describes a method for producing a sheet-shaped cell culture with high cytokine production capacity, and in the method, it is stated that the cytokine production capacity of the sheet-shaped cell culture is increased by providing a step of freezing and thawing the cells when producing the sheet-shaped cell culture. Patent Document 3 describes a method for selecting pluripotent mesenchymal stem cells having high proliferation capacity (passage number, colony formation efficiency) from pluripotent mesenchymal stem cells using flow cytometry. Patent Document 4 describes a method for preparing an amniotic mesenchymal stem cell population, including: (A) a step of collecting a cell population of mesenchymal cells from a mammalian amniotic membrane; (B) a step of (b1) detecting forward scattered light and side scattered light using a flow cytometer to create a two-dimensional distribution map of the cell population of mesenchymal cells, (b2) a step of separating selected cells by setting a rectangular three-division gate on the two-dimensional distribution map, and (C) a step of subculturing the separated cells. [Prior art documents] [Patent documents]
[0005] [Patent Document 1] JP 2015-61520 A [Patent Document 2] JP 2015-15963 A [Patent Document 3] Special Publication No. 2014-501110 [Patent Document 4] International Publication No. WO2013 / 077428 Summary of the Invention [Problem to be solved by the invention]
[0006] In a preliminary study by the present inventors, it was found that since mesenchymal stem cells have low proliferation properties (low specific proliferation rate), it is not necessarily easy to prepare and produce a large amount of cells required for cell preparation quickly. However, Patent Document 1 does not describe at all the selective preparation of mesenchymal stem cells having specific excellent characteristics from mesenchymal stem cells, specifically, the acquisition of mesenchymal stem cells having a high specific proliferation rate useful for the rapid production of cell preparations in large quantities. Moreover, Patent Documents 2 and 3 do not describe at all the acquisition of mesenchymal stem cells having a high specific proliferation rate useful for the rapid production of cell preparations in large quantities. Patent Document 4 describes the preparation of an amniotic mesenchymal stem cell population having high proliferation and differentiation potential from a cell population of amniotic mesenchymal cells, but this is a method of separating cells by flow cytometry. Patent Document 4 does not describe or suggest that there is a cell population with large long and short axes and a cell population with small long and short axes in the amniotic mesenchymal stem cell population, or that the resistance of the above two types of cells to physical or chemical stimuli is different.
[0007] As described above, attempts have been made to obtain cells with excellent cytokine production ability, passage number, and colony formation efficiency from specific cell populations. However, there has been no idea or attempt to produce mesenchymal stem cells with a high specific proliferation rate, which is useful for producing cell preparations in a large amount and quickly, from mesenchymal stem cells through treatment with physical or chemical stimulation.
[0008] An objective of the present invention is to provide a method for producing a cell population containing mesenchymal stem cells (MSCs) with a high specific proliferation rate, which is useful for the rapid mass production of cell preparations, the mesenchymal stem cells, a cell population containing the mesenchymal stem cells (mesenchymal stem cell population), and a pharmaceutical composition containing the mesenchymal stem cells or the cell population. [Means for solving the problem]
[0009] The present inventors have found that mesenchymal stem cells include two or more types of cells with different proliferation rates, that these cells have different resistance to physical or chemical stimuli, and that by treating a cell population containing the above two or more types of mesenchymal stem cells with physical or chemical stimuli, mesenchymal stem cells with low proliferation rates can be selected out, in other words, mesenchymal stem cells with low proliferation rates can be killed or their proliferation (specific proliferation rate) can be significantly reduced (i.e., the cells can be made difficult to proliferate). Furthermore, the present inventors have identified that the characteristics of mesenchymal stem cells with high proliferation rates are that they are CD106 negative and have increased expression of metallothionein family genes.
[0010] Based on these findings, the present inventors have found that by treating a cell population containing mesenchymal stem cells with different proliferation potentials with physical or chemical stimuli, it is possible to select and obtain live mesenchymal stem cells with relatively high proliferation potential, that the characteristics of mesenchymal stem cells with relatively high proliferation potential are that they are CD106 negative and have increased expression levels of metallothionein family genes, or that the content of mesenchymal stem cells with relatively high proliferation potential can be increased. Furthermore, they have found that a cell population containing a large amount of mesenchymal stem cells with relatively high proliferation potential has a high specific proliferation rate and is extremely suitable for the rapid mass production of cells, and that by culturing and amplifying the cells (cell population), a cell preparation can be produced rapidly and in large quantities. The present invention has been completed based on the above-mentioned viewpoints and ideas, and the above-mentioned obtained findings.
[0011] That is, according to the present specification, the following invention is provided. [1] A method for producing a cell population containing mesenchymal stem cells, comprising: The method includes a selection step of selecting mesenchymal stem cells having a relatively high proliferation ability by treating a cell population containing mesenchymal stem cells having different proliferation abilities with a physical or chemical stimulus, A method for producing the cell population, characterized in that the selected mesenchymal stem cells with relatively high proliferative potential are CD106 negative and the expression level of metallothionein family genes is increased compared to before treatment with the physical or chemical stimulus. [2] The method for producing a cell population described in [1], wherein the step of treating the cell population containing mesenchymal stem cells with different proliferation abilities with a physical stimulus comprises freezing the cell population and then thawing it. [3] The method for producing a cell population described in [1] or [2], wherein treating the cell population containing mesenchymal stem cells with different proliferation abilities with a physical stimulus comprises the steps of suspending the cell population in a cryopreservation solution, freezing the resulting suspension to maintain the frozen state, and thawing. [4] The method for producing a cell population described in [3], wherein the frozen state is maintained for two days or more. [5] A method for producing a cell population described in any one of [1] to [4], further comprising a step of culturing and / or passaging the cell population containing mesenchymal stem cells obtained in the selection step. [6] A method for producing a cell population described in any one of [1] to [5], further comprising a cell population obtaining step of obtaining a cell population containing mesenchymal stem cells with different proliferation abilities by enzymatic treatment of fetal appendages. [7] The method for producing a cell population described in [6], further comprising a step of culturing the cell population obtained in the cell population obtaining step. [8] A method for producing a cell population described in any one of [1] to [7], wherein the metallothionein family gene is at least one selected from the group consisting of MT1E, MT1F, MT1G, MT1H, MT1X and MT2A. [9] A method for producing a cell population described in any one of [1] to [8], wherein the selected mesenchymal stem cells having relatively high proliferation ability are SA-β-Gal negative.
[10] The method for producing a cell population described in [9], wherein the average ratio of mesenchymal stem cells that are SA-β-Gal negative in the cell population is 90% or more.
[11] A method for producing a cell population described in any one of [1] to
[10] , wherein the selected mesenchymal stem cells with relatively high proliferation ability are CD105 positive, CD73 positive, CD90 positive, CD45 negative, CD34 negative, CD11b negative, CD79alpha negative, and HLA-DR negative.
[12] A method for producing a cell population described in any one of [1] to
[11] , wherein the specific proliferation rate of the selected mesenchymal stem cells having relatively high proliferation potential is 0.14 (1 / day) or more.
[13] A method for producing a cell population described in any one of [1] to
[11] , wherein the average diameter of the selected mesenchymal stem cells in a suspended state having relatively high proliferation ability is 80% or less of the average diameter of the mesenchymal stem cells in a suspended state having relatively low proliferation ability.
[14] Mesenchymal stem cells that are CD106 negative and have increased expression of metallothionein family genes compared to cells before treatment with physical or chemical stimuli.
[15] The mesenchymal stem cell described in
[14] , wherein the metallothionein family gene is at least one selected from the group consisting of MT1E, MT1F, MT1G, MT1H, MT1X and MT2A.
[16] The mesenchymal stem cells described in
[14] or
[15] , wherein the mesenchymal stem cells are SA-β-Gal negative.
[17] The mesenchymal stem cells described in any one of
[14] to
[16] , wherein the mesenchymal stem cells are CD105 positive, CD73 positive, CD90 positive, CD45 negative, CD34 negative, CD11b negative, CD79alpha negative, and HLA-DR negative.
[18] The mesenchymal stem cells described in any one of
[14] to
[17] , wherein the specific proliferation rate of the mesenchymal stem cells is 0.14 (1 / day) or more.
[19] Mesenchymal stem cells described in any one of
[14] to
[18] , wherein the average diameter of the mesenchymal stem cells in a suspended state is 80% or less of the average diameter of mesenchymal stem cells in a suspended state having relatively low proliferation ability.
[20] A cell population comprising mesenchymal stem cells, The cell population, wherein the mesenchymal stem cells express an increased amount of metallothionein family genes compared to cells before the treatment with physical or chemical stimulation, and are CD106 negative.
[21] The cell population described in
[20] , wherein the proportion of mesenchymal stem cells that are CD106 positive in the cell population is less than 5%.
[22] The cell population described in
[20] or
[21] , wherein the average proportion of mesenchymal stem cells that are SA-β-Gal negative in the cell population is 90% or more.
[23] A pharmaceutical composition comprising the mesenchymal stem cell described in any one of
[14] to
[19] or the cell population described in any one of
[20] to
[22] , and a pharma- ceutical acceptable vehicle.
[24] A single dose of mesenchymal stem cells in humans was 9 The pharmaceutical composition according to
[23] , wherein the dosage is less than or equal to 1 piece / kg body weight.
[25] The pharmaceutical composition according to
[23] or
[24] , which is a therapeutic agent for a disease selected from immune-related diseases, graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, collagen disease, radiation enteritis, liver cirrhosis, stroke, or atopic dermatitis.
[0012]
[26] Mesenchymal stem cells obtained by the manufacturing method described in any one of [1] to
[13] .
[27] Use of a mesenchymal stem cell described in any one of
[14] to
[19] or a cell population described in any one of
[20] to
[22] for the manufacture of a pharmaceutical composition.
[28] The pharmaceutical composition comprises a single dose of mesenchymal stem cells for administration to a human being of 10 9 The use described in
[27] , wherein the pharmaceutical composition has a dosage of 100 or less per kg of body weight.
[29] The use described in
[27] or
[28] , wherein the pharmaceutical composition is a therapeutic agent for a disease selected from immune-related diseases, graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, collagen disease, radiation enteritis, liver cirrhosis, stroke, or atopic dermatitis.
[30] A mesenchymal stem cell according to any one of
[14] to
[19] or a cell population according to any one of
[20] to
[22] for use in the treatment of a disease.
[31] A single dose of mesenchymal stem cells in humans was 9 The mesenchymal stem cell or cell population described in
[30] , wherein the number of cells or the cell population is less than or equal to 100 / kg body weight.
[32] The mesenchymal stem cell or cell population according to
[30] or
[31] , wherein the disease is selected from immune-related diseases, graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, collagen disease, radiation enteritis, liver cirrhosis, stroke, or atopic dermatitis.
[33] A method for treating a disease, comprising administering to a patient in need of treatment the mesenchymal stem cell described in any one of
[14] to
[19] or the cell population described in any one of
[20] to
[22] .
[34] A single dose of mesenchymal stem cells in humans was 9 A method for treating the disease described in
[33] , wherein the number of cells per kg of body weight or less.
[35] The method for treating a disease described in
[33] or
[34] , wherein the disease is selected from immune-related diseases, graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, collagen disease, radiation enteritis, liver cirrhosis, stroke, or atopic dermatitis.
[36] A composition comprising the mesenchymal stem cells described in any one of
[14] to
[19] and a medium.
[37] A composition comprising a cell population described in any one of
[20] to
[22] and a medium. Effect of the Invention
[0013] According to the present invention, mesenchymal stem cells (cell population) with a high specific proliferation rate can be obtained, which allows rapid mass production of cell preparations (pharmaceutical compositions). For example, 2.3 × 10 3 (pcs / cm 2 / day) or more of cells can be prepared / produced. Furthermore, according to the present invention, it is possible to obtain mesenchymal stem cells (cell population) with improved resistance to freezing / thawing. [Brief description of the drawings]
[0014] [Figure 1]FIG. 1 shows a trypan blue stained image of suspended amniotic membrane MSCs immediately after the freeze-thaw treatment in step 1-5 of Example 1. [Diagram 2] FIG. 2 shows a phase contrast microscope image of the pre-cultured 2 cells (amniotic membrane MSCs before the freeze-thaw treatment) obtained in steps 1-4 of Example 1 at confluence. [Diagram 3] FIG. 3 shows a phase contrast microscope image of the main culture 1 cells obtained in steps 1-6 of Example 1 (amniotic membrane MSCs cultured once after freeze-thaw treatment) at confluence. [Figure 4] FIG. 4 shows a phase contrast microscope image of the passage 1 cells obtained in steps 1-6 of Example 1 (amniotic membrane MSCs passaged once after freeze-thaw treatment) at confluence. [Diagram 5] FIG. 5 shows an image of SA-β-Gal staining of pre-cultured 2 cells (amniotic membrane MSCs before the freeze-thaw treatment) obtained in step 1-4 of Example 1. [Figure 6] FIG. 6 shows an image of SA-β-Gal staining of pre-cultured 3 cells (amniotic membrane MSCs before undergoing the freeze-thaw treatment) obtained in step 3-5 of Example 3. [Figure 7] FIG. 7 shows an image of SA-β-Gal staining of passage 2 cells obtained in step 3-9 of Example 3 (amniotic membrane MSCs passaged twice after freeze-thaw treatment). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0015] The following describes the embodiments of the present invention in detail. The following description is intended to facilitate understanding of the present invention, and the scope of the present invention is not limited to the embodiments described below. Other embodiments in which a person skilled in the art appropriately replaces the configuration of the embodiments described below are also included in the scope of the present invention.
[0016] [1] Explanation of terms In this specification, "fetal appendages" refers to the fetal membrane, placenta, umbilical cord, and amniotic fluid. Furthermore, the "fetal membrane" is a gestational sac containing fetal amniotic fluid, and is composed of the amnion, chorion, and decidua from the inside out. Of these, the amnion and chorion originate from the fetus. The "amnion" refers to a transparent thin film with few blood vessels that is the innermost layer of the fetal membrane. The inner layer of the amnion (also called the epithelial cell layer) is covered with a single layer of epithelial cells with secretory function and secretes amniotic fluid, and the outer layer of the amnion (also called the extracellular matrix layer, equivalent to the interstitium) contains mesenchymal stem cells.
[0017] As used herein, "mesenchymal stem cells (MSCs)" refer to stem cells that meet the following definition and are used interchangeably with "mesenchymal stromal cells." As used herein, "mesenchymal stem cells" may also be referred to as "MSCs."
[0018] Definition of Mesenchymal Stem Cells i) When cultured in standard medium, they exhibit adhesion to plastic. ii) Surface antigens CD105, CD73, and CD90 are positive, and CD45, CD34, CD11b, CD79alpha, and HLA-DR are negative.
[0019] In the present specification, the term "amniotic mesenchymal stem cells" refers to mesenchymal stem cells derived from the amniotic membrane, and is used interchangeably with "amniotic mesenchymal stromal cells." In the present specification, "amniotic mesenchymal stem cells" may also be referred to as "amniotic MSCs."
[0020] As used herein, the term "mesenchymal stem cell population" refers to a cell population containing mesenchymal stem cells, and the form thereof is not particularly limited, and examples include a cell pellet, a cell aggregate, a cell suspension, or a cell suspension.
[0021] A cell population containing mesenchymal stem cells with different proliferation capabilities means a cell population containing at least mesenchymal stem cells with relatively high proliferation capabilities and mesenchymal stem cells with relatively low proliferation capabilities. The present inventors have found that the mesenchymal stem cells with relatively low proliferation capabilities have relatively low resistance to physical or chemical stimuli, while the mesenchymal stem cells with relatively high proliferation capabilities have relatively high resistance to physical or chemical stimuli. When there are two types of mesenchymal stem cells with different proliferation capabilities, the cells with relatively high proliferation capabilities are called "mesenchymal stem cells with relatively high proliferation capabilities" and the cells with relatively low proliferation capabilities are called "mesenchymal stem cells with relatively low proliferation capabilities".
[0022] In this specification, the term "cell number obtained per culture batch" refers to the number of cells obtained per unit surface area of the culture vessel and per unit number of culture days in one culture. Therefore, the unit of "cell number obtained per culture batch" is (cells / cm 2 / day).
[0023] In this specification, "relatively" means higher or lower or larger or smaller than the corresponding counterpart. For example, in a cell population containing mesenchymal stem cells with different proliferation potential, when the cells are classified into mesenchymal stem cells with high proliferation potential and mesenchymal stem cells with low proliferation potential using proliferation potential as an index, the former mesenchymal stem cells with high proliferation potential are referred to as "mesenchymal stem cells with relatively high proliferation potential" and the latter mesenchymal stem cells with low proliferation potential are referred to as "mesenchymal stem cells with relatively low proliferation potential".
[0024] Similarly, for a cell population containing cells of different sizes, when the cells are classified into large and small cells using size as an indicator, the former large cells are referred to as "relatively large cells" and the latter small cells are referred to as "relatively small cells."
[0025] As used herein, the term "proliferative capacity" refers to the capacity of cells to increase in number by cell division. The proliferative capacity of mesenchymal stem cells (MSCs) in a mesenchymal stem cell population can be evaluated using the specific proliferation rate. The method for measuring the specific proliferation rate is described later in this specification.
[0026] [2] A method for producing a cell population containing mesenchymal stem cells The method for producing a cell population containing mesenchymal stem cells according to the present invention is a method comprising a selection step of treating a cell population containing mesenchymal stem cells (MSCs) with different proliferation potential with a physical or chemical stimulus to select mesenchymal stem cells with relatively high proliferation potential.
[0027] The phrase "selecting mesenchymal stem cells with relatively high proliferation potential" refers to eliminating mesenchymal stem cells with a relatively low proliferation rate, in other words, to a state in which the proportion of mesenchymal stem cells with relatively high proliferation potential in a cell population containing mesenchymal stem cells is increased by killing mesenchymal stem cells with a relatively low proliferation rate or significantly reducing their proliferation ability (specific proliferation rate), but is not particularly limited to this state.
[0028] A cell population containing MSCs with different proliferation potential is a cell population containing at least MSCs with relatively high proliferation potential and MSCs with relatively low proliferation potential.
[0029] The production method of the present invention may include a cell population obtaining step of obtaining a cell population containing MSCs with different proliferation capabilities by enzymatically treating a sample (for example, fetal appendages such as the amnion).
[0030] The amniotic membrane consists of an epithelial cell layer and an extracellular matrix layer, the latter of which contains amniotic MSCs. Like other epithelial cells, amniotic epithelial cells characteristically express epithelial cadherin (E-cadherin: CD324) and epithelial adhesion factor (EpCAM: CD326), whereas amniotic MSCs do not express these epithelial-specific surface antigen markers and can be easily distinguished by flow cytometry. The above-mentioned cell population obtaining step may include a step of obtaining the amniotic membrane by Caesarean section.
[0031] The enzymatic treatment of the sample (e.g., fetal appendages such as the amnion) is preferably a treatment with an enzyme (or a combination thereof) capable of releasing MSCs contained in the extracellular matrix layer of the sample and not degrading the epithelial cell layer of the sample. Such enzymes include, but are not limited to, collagenase and / or metalloproteinase. Metalloproteinases include, but are not limited to, thermolysin and / or dispase, which are metalloproteinases that cleave the N-terminal side of non-polar amino acids.
[0032] The collagenase concentration is preferably 50 CDU / ml or more, more preferably 75 CDU / ml or more, even more preferably 100 CDU / ml or more, even more preferably 125 CDU / ml or more, even more preferably 150 CDU / ml or more. The collagenase concentration is not particularly limited, but is, for example, 1000 CDU / ml or less, 900 CDU / ml or less, 800 CDU / ml or less, 700 CDU / ml or less, 600 CDU / ml or less, 500 CDU / ml or less, 400 CDU / ml or less, or 300 CDU / ml or less. Here, CDU (collagen digestion unit) is defined as the amount of enzyme that produces amino acids and peptides equivalent to 1 μmol of leucine in 5 hours at 37° C. and pH 7.5 using collagen as a substrate. The concentration of metal proteinase (e.g., thermolysin and / or dispase) is preferably 100 PU / ml or more, more preferably 125 PU / ml or more, even more preferably 150 PU / ml or more, even more preferably 175 PU / ml or more, even more preferably 200 PU / ml or more. The concentration of metal proteinase is preferably 800 PU / ml or less, more preferably 700 PU / ml or less, even more preferably 600 PU / ml or less, even more preferably 500 PU / ml or less, even more preferably 400 PU / ml or less. Here, PU (protease unit) is defined as the amount of enzyme that produces amino acids and peptides equivalent to 1 μg of tyrosine per minute at 35 ° C. and pH 7.2 using lactate casein as a substrate. In the above enzyme concentration range, MSCs contained in the extracellular matrix layer can be efficiently released while preventing contamination of epithelial cells contained in the epithelial cell layer of the sample. If the collagenase concentration is less than 50 CDU / ml or the metal proteinase concentration is less than 100 CDU / ml, the extracellular matrix layer will not be sufficiently digested, and the recovery rate of MSCs may be significantly reduced. If the metal proteinase concentration is greater than 800 CDU / ml, epithelial cells may be mixed into the digestive fluid due to the decomposition of the epithelial cell layer, and the recovery rate of MSCs may be relatively reduced. The preferred combination of collagenase and / or metal proteinase concentrations can be determined by microscopic observation of the sample after enzyme treatment or flow cytometry of the obtained cells.In addition, it is preferable to treat MSCs that contain almost no epithelial cells with a physical or chemical stimulus, as described below.
[0033] From the viewpoint of efficiently recovering living cells, it is preferable to treat the sample simultaneously and in a lump with a combination of collagenase and metal proteinase. In this case, the metal proteinase may be, but is not limited to, thermolysin and / or dispase. By treating the sample only once with an enzyme solution containing collagenase and metal proteinase, MSCs can be easily obtained. In addition, by treating simultaneously and in a lump, the risk of contamination by bacteria, viruses, etc. can be reduced.
[0034] The enzyme treatment of the sample is preferably performed by immersing the sample washed with a washing solution such as physiological saline or Hanks' balanced salt solution in the enzyme solution and treating the sample while stirring with a stirring means. As the stirring means, from the viewpoint of efficiently releasing MSC contained in the extracellular matrix layer of the sample, for example, a stirrer or a shaker can be used, but is not limited thereto. The stirring speed is not particularly limited, but when a stirrer or a shaker is used, for example, 5 rpm or more, 10 rpm or more, 20 rpm or more, 30 rpm or more, 40 rpm or more, or 50 rpm or more. In addition, the stirring speed is not particularly limited, but when a stirrer or a shaker is used, for example, 100 rpm or less, 90 rpm or less, 80 rpm or less, 70 rpm or less, or 60 rpm or less. The enzyme treatment time is not particularly limited, but for example, 10 minutes or more, 20 minutes or more, 30 minutes or more, 40 minutes or more, 50 minutes or more, or 60 minutes or more. The enzyme treatment time is not particularly limited, but may be, for example, 6 hours or less, 5 hours or less, 4 hours or less, 3 hours or less, 2 hours or less, 110 minutes or less, 100 minutes or less, 90 minutes or less, 80 minutes or less, or 70 minutes or less. The enzyme treatment temperature is not particularly limited, but may be, for example, 15°C or more, 16°C or more, 17°C or more, 18°C or more, 19°C or more, 20°C or more, 21°C or more, 22°C or more, 23°C or more, 24°C or more, 25°C or more, 26°C or more, 27°C or more, 28°C or more, 29°C or more, 30°C or more, 31°C or more, 32°C or more, 33°C or more, 34°C or more, 35°C or more, or 36°C or more. The enzyme treatment temperature is not particularly limited, but may be, for example, 40°C or less, 39°C or less, 38°C or less, or 37°C or less.
[0035] In the production method of the present invention, if desired, the enzyme solution containing the liberated MSCs can be filtered through a filter. Only the liberated cells pass through the filter, and the epithelial cell layer that has not been decomposed cannot pass through the filter and remains on the filter, so that not only can the liberated MSCs be easily collected, but also the risk of contamination by bacteria, viruses, etc. can be reduced. The filter is not particularly limited, but for example, a mesh filter can be mentioned. The pore size (mesh size) of the mesh filter is not particularly limited, but for example, 40 μm or more, 50 μm or more, 60 μm or more, 70 μm or more, 80 μm or more, 90 μm or more, 100 μm or more, 110 μm or more, 120 μm or more, 130 μm or more, or 140 μm or more. In addition, the pore size of the mesh filter is not particularly limited, but for example, 200 μm or less, 190 μm or less, 180 μm or less, 170 μm or less, 160 μm or less, or 150 μm or less. There are no particular limitations regarding the filtration rate, but by setting the pore size of the mesh filter within the above range, the enzyme solution containing MSCs can be filtered by gravity, thereby preventing a decrease in cell viability.
[0036] Nylon is preferably used as the material for the mesh filter. Tubes containing 40 μm, 70 μm, or 100 μm nylon mesh filters, such as Falcon cell strainers, which are widely used for research, can be used. Medical mesh cloths (nylon and polyester) used in hemodialysis can also be used. Furthermore, arterial filters (polyester mesh filters, pore size: 40 μm to 120 μm) used during extracorporeal circulation can also be used. Other materials, such as stainless steel mesh filters, can also be used.
[0037] When passing MSCs through a filter, gravity (free fall) is preferred. Forced passage through a filter, such as by suction using a pump, is also possible, but it is desirable to use as little pressure as possible to avoid damaging the cells.
[0038] The filtered MSCs can be collected by centrifugation after diluting the filtrate with twice or more volumes of culture medium or balanced salt buffer, such as, but not limited to, Dulbecco's phosphate buffered saline (DPBS), Earle's balanced salt solution (EBSS), Hank's balanced salt solution (HBSS), and phosphate buffered saline (PBS).
[0039] The cell population obtained in the cell population obtaining step can be expanded by culture before the selection step, if desired. That is, the production method of the present invention may further include a step of culturing the cell population obtained in the cell population obtaining step. Such culturing (pre-culture) is preferably performed in a plastic dish or flask in an environment with a CO2 concentration of 3% to 5% at 37°C. Furthermore, in the step of culturing the cell population obtained in the cell population obtaining step, the cells may be passaged one or more times.
[0040] The medium used for the above culture is not particularly limited, but examples thereof include αMEM (Alpha Modification of Minimum Essential Medium Eagle), DMEM, BME, BGJb, CMRL1066, Glasgow MEM, Improved MEM Zinc Option, IMDM (Iscove's Modified Dulbecco's Medium), Eagle MEM, RPMI1640, M199, Ham's F10 medium, Ham's F12 medium, Fischer's medium, mixed medium (e.g., DMEM / F12 medium), serum-free medium, or media based on these. Examples of serum-free media include, but are not limited to, STK1, STK2 (DS Pharma Biomedical), EXPREP MSC Medium (Biomimetics Sympathies), Corning stemgro human mesenchymal stem cell medium (Corning). These media may contain, but are not limited to, other components such as albumin, serum, serum replacement reagents, growth factors, and growth factor stabilizing reagents (e.g., heparin) as needed. In the case of albumin, a concentration of more than 0.05% and not more than 5% is preferable. In the case of serum, a concentration of 5% or more is preferable.
[0041] The production method of the present invention includes a selection step of treating a cell population containing MSCs with different proliferation potential with a physical or chemical stimulus (preferably a physical stimulus) to select MSCs with relatively high proliferation potential.
[0042] The type of physical or chemical stimulus is not particularly limited as long as it can separate MSCs with relatively high proliferation potential from MSCs with relatively low proliferation potential. For example, the type of physical or chemical stimulus can be, but is not particularly limited to, a stimulus that is more resistant to the stimulus by MSCs with relatively high proliferation potential than by MSCs with relatively low proliferation potential.
[0043] Examples of physical stimuli include, but are not limited to, freezing and thawing, heating, filtration, centrifugation, electrophoresis, voltage application, pressure application, pressure reduction, osmotic pressure change, ultraviolet irradiation, ultrasonic irradiation, etc. A plurality of physical stimuli can be applied individually or in combination, but are not limited thereto.
[0044] Examples of chemical stimuli include, but are not limited to, gene transfer, treatment with a cytotoxic compound, treatment with an acid or base to change the pH, etc. Multiple chemical stimuli can be applied individually or in combination, but are not limited thereto.
[0045] A preferred example of the physical stimulus is freezing and then thawing a cell population containing MSCs with different proliferation capabilities, while a more preferred embodiment of the physical stimulus is suspending a cell population containing MSCs with different proliferation capabilities in a cryopreservation solution, freezing the resulting suspension to maintain the frozen state, and then thawing.
[0046] A preferred example of chemical stimulation is gene transfer into a cell population containing CD106-negative MSCs using a vector containing a base sequence of a metallothionein family gene. More specific examples of gene transfer include, but are not limited to, gene transfer using a virus vector (e.g., retrovirus vector, lentivirus vector, adenovirus vector, adeno-associated virus vector, etc.) or a non-virus vector (e.g., plasmid DNA, artificial chromosome vector, etc.).
[0047] The above-mentioned cryopreservation solution preferably contains a polysaccharide at a predetermined concentration from the viewpoint of increasing the survival rate of MSCs with relatively high proliferation ability. The preferred polysaccharide concentration is, for example, 1% by mass or more, 2% by mass or more, 3% by mass or more, 4% by mass or more, 5% by mass or more, 6% by mass or more, 7% by mass or more, 8% by mass or more, 9% by mass or more, 10% by mass or more, 11% by mass or more, or 12% by mass or more. The preferred polysaccharide concentration is, for example, 40% by mass or less, 35% by mass or less, 30% by mass or less, 25% by mass or less, 20% by mass or less, 19% by mass or less, 18% by mass or less, 17% by mass or less, 16% by mass or less, 15% by mass or less, 14% by mass or less, or 13% by mass or less. Examples of polysaccharides include, but are not limited to, hydroxyethyl starch (HES) or dextran (Dextran 40, etc.).
[0048] The above-mentioned cryopreservation solution preferably contains a predetermined concentration of dimethyl sulfoxide (DMSO) from the viewpoint of efficiently selecting MSCs with relatively high proliferation ability. The preferred concentration of DMSO is, for example, 1% by mass or more, 2% by mass or more, 3% by mass or more, 4% by mass or more, 5% by mass or more, 6% by mass or more, 7% by mass or more, 8% by mass or more, or 9% by mass or more. The preferred concentration of DMSO is, for example, 20% by mass or less, 19% by mass or less, 18% by mass or less, 17% by mass or less, 16% by mass or less, 15% by mass or less, 14% by mass or less, 13% by mass or less, 12% by mass or less, 11% by mass or less, or 10% by mass or less.
[0049] The above-mentioned cryopreservation solution preferably contains albumin at a predetermined concentration of more than 0% by mass in order to increase the survival rate of MSCs with relatively high proliferation ability. The preferred concentration of albumin is, for example, 0.5% by mass or more, 1% by mass or more, 2% by mass or more, 3% by mass or more, 4% by mass or more, 5% by mass or more, 6% by mass or more, 7% by mass or more, or 8% by mass or more. The preferred concentration of albumin is, for example, 40% by mass or less, 35% by mass or less, 30% by mass or less, 25% by mass or less, 20% by mass or less, 15% by mass or less, 10% by mass or less, or 9% by mass or less. Examples of albumin include, but are not limited to, bovine serum albumin, mouse albumin, and human albumin.
[0050] The means for freezing the cell population containing MSCs with different proliferation capabilities is not particularly limited, and examples thereof include a programmed freezer, a deep freezer, and immersion in liquid nitrogen. The preferred temperature for freezing is, for example, -30°C or lower, -40°C or lower, -50°C or lower, -60°C or lower, -70°C or lower, -80°C or lower, -90°C or lower, -100°C or lower, -110°C or lower, -120°C or lower, or -130°C or lower. The preferred temperature for freezing is, for example, -196°C (liquid nitrogen temperature) or higher, -190°C or higher, -180°C or higher, -170°C or higher, -160°C or higher, -150°C or higher, or -140°C or higher. The freezing rate is preferably, for example, -1°C / min, -2°C / min, -3°C / min, -4°C / min, -5°C / min, -6°C / min, -7°C / min, -8°C / min, -9°C / min, -10°C / min, -11°C / min, -12°C / min, -13°C / min, -14°C / min, or -15°C / min. When a programmable freezer is used as the freezing means, the temperature can be lowered to a temperature between -50°C and -30°C (e.g., -40°C) at a freezing rate of -2°C / min to -1°C / min, and further lowered to a temperature between -100°C and -80°C (e.g., -90°C) at a freezing rate of -11°C / min to -9°C / min (e.g., -10°C / min).
[0051] When freezing by the above freezing means, the cell population may be frozen in any storage container, such as, but not limited to, cryotubes, cryovials, freezing bags, infusion bags, etc.
[0052] From the viewpoint of efficiently selecting MSCs with relatively high proliferation ability, the frozen cell population is preferably maintained for a predetermined period of time at a temperature at which the frozen state can be maintained. The upper limit of the temperature at which the frozen state is maintained is, for example, -130°C or lower, -140°C or lower, or -150°C or lower. The lower limit of the temperature at which the frozen state is maintained is, for example, -196°C (liquid nitrogen temperature) or higher, -190°C or higher, -180°C or higher, -170°C or higher, or -160°C or higher. Since the glass transition temperature of the cytoplasm is -130°C, if the temperature at which the frozen state is maintained is higher than -130°C, ice crystals may form in the cells, resulting in a decrease in cell viability. The lower limit of the preferred period for maintaining the frozen state is, for example, 12 hours or more, 16 hours or more, 20 hours or more, 24 hours or more, 30 hours or more, 36 hours or more, 42 hours or more, 2 days or more, 3 days or more, 4 days or more, 5 days or more, 6 days or more, 7 days or more, 8 days or more, 9 days or more, 10 days or more, 11 days or more, 12 days or more, 13 days or more, 14 days or more, 15 days or more, 16 days or more, 17 days or more, 18 days or more, 19 days or more, 20 days or more, 21 days or more, 22 days or more, 23 days or more, 24 days or more, 25 days or more, 26 days or more, 27 days or more, 28 days or more, 29 days or more, 30 days or more, or 31 days or more. In addition, the upper limit of the period for which the information is maintained in a frozen state is not particularly limited, but is, for example, 20 years or less, 10 years or less, 5 years or less, 4 years or less, 3 years or less, 2 years or less, 1 year or less, 11 months or less, 10 months or less, 9 months or less, 8 months or less, 7 months or less, 6 months or less, 5 months or less, 4 months or less, 3 months or less, 2 months or less, or 1 month or less.
[0053] The means for thawing the frozen cell population includes, but is not limited to, contact (e.g., immersion) with a medium (e.g., solid, liquid, gas) having a temperature higher than the freezing temperature. The lower limit of the temperature of the medium is not particularly limited, but is, for example, 1°C or higher, 2°C or higher, 3°C or higher, 4°C or higher, 5°C or higher, 6°C or higher, 7°C or higher, 8°C or higher, 9°C or higher, 10°C or higher, 11°C or higher, 12°C or higher, 13°C or higher, 14°C or higher, 15°C or higher, 16°C or higher, 17°C or higher, 18°C or higher, 19°C or higher, 20°C or higher, 21°C or higher, 22°C or higher, 23°C or higher, 24°C or higher, 25°C or higher, 26°C or higher, 27°C or higher, 28°C or higher, 29°C or higher, 30°C or higher, 31°C or higher, 32°C or higher, 33°C or higher, 34°C or higher, 35°C or higher, or 36°C or higher. The upper limit of the temperature of the medium is not particularly limited, but may be, for example, 50° C. or less, 49° C. or less, 48° C. or less, 47° C. or less, 46° C. or less, 45° C. or less, 44° C. or less, 43° C. or less, 42° C. or less, 41° C. or less, 40° C. or less, 39° C. or less, 38° C. or less, or 37° C. or less. The time required for thawing is not particularly limited, but may be, for example, 10 seconds, 20 seconds, 30 seconds, 40 seconds, 50 seconds, 60 seconds (1 minute), 70 seconds, 80 seconds, 90 seconds, 100 seconds, 110 seconds, 120 seconds (2 minutes), 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, or 10 minutes. For example, when thawing 1 ml of frozen cell suspension in a 2 ml polypropylene cryotube (outer diameter: 13.5 mm) in a thermostatic bath at 37° C., it can be thawed within 2 minutes. For example, 20 ml of frozen cell suspension in a 25 ml polyolefin freezing bag (external dimensions: 81 mm × 121.5 mm) can be thawed within 5 minutes in a thermostatic bath at 37° C. Rapid thawing can improve the survival rate of MSCs, which have a relatively high proliferation ability.
[0054] The cell population containing MSC obtained in the above-mentioned selection step can be further cultured and / or passaged, thereby obtaining a large amount of MSC with relatively high proliferation ability (MSC with a high specific proliferation rate, described later), and further increasing the content of MSC with relatively high proliferation ability in the obtained cell population. That is, the production method of the present invention may further include a step of culturing and / or passage of the cell population containing MSC obtained in the selection step. The content of the MSC with relatively high proliferation ability in the mesenchymal stem cell population obtained by culture and / or passage after the selection step is 10% or more, preferably 20% or more, more preferably 30% or more, more preferably 40% or more, more preferably 50% or more, more preferably 60% or more, more preferably 70% or more, more preferably 80% or more, more preferably 90% or more, more preferably 95% or more, more preferably 98% or more, more preferably 99% or more, and particularly preferably 100%. The content of MSCs with relatively high proliferation potential in the cell population before stimulation treatment varies depending on the donor, but the present inventors have found that this content is generally 1% or less, as shown in the Examples below.
[0055] The culture (main culture) of MSC obtained in the above-mentioned selection process can be carried out, for example, by the following steps. First, the thawed cell suspension after the freeze-thaw process is centrifuged, the supernatant is removed, and the obtained cell pellet is suspended in a medium. Next, the cells are seeded in a plastic culture vessel and cultured in a medium at a CO2 concentration of 3% to 5% and at 37°C to a confluence rate of 95% or less. Examples of the above-mentioned medium include, but are not limited to, αMEM, DMEM, BME, BGJb, CMRL1066, Glasgow MEM, Improved MEM Zinc Option, IMDM, Eagle MEM, RPMI1640, M199, Ham's F10 medium, Ham's F12 medium, Fischer's medium, mixed medium (e.g., DMEM / F12 medium), serum-free medium, or medium based on these. Additional components such as albumin, serum, serum replacement reagent, growth factor, and growth factor stabilization reagent may be added to these media as necessary, but are not particularly limited thereto. The cells obtained by the above-mentioned culture (main culture) are cells that have been cultured once.
[0056] The cells cultured once can be further subcultured and cultured, for example, as follows. First, the cells cultured once are treated with ethylenediaminetetraacetic acid (EDTA) and then with trypsin to detach them from the plastic culture vessel. Next, the obtained cell suspension is centrifuged, the supernatant is removed, and the obtained cell pellet is suspended in a medium. Finally, the cells are seeded in a plastic culture vessel and cultured in a medium at a CO2 concentration of 3% to 5% and at 37°C to a confluence rate of 95% or less. Examples of the medium include, but are not limited to, αMEM, DMEM, BME, BGJb, CMRL1066, Glasgow MEM, Improved MEM Zinc Option, IMDM, Eagle MEM, RPMI1640, M199, Ham's F10 medium, Ham's F12 medium, Fischer's medium, mixed medium (e.g., DMEM / F12 medium), serum-free medium, or media based on these. These media may contain additional components such as, but are not limited to, albumin, serum, serum replacement reagent, growth factor, and growth factor stabilizing reagent, as necessary. The cells obtained by the above-mentioned passaging and culturing are cells that have been passaged once. By performing the same passaging and culturing, cells that have been passaged N times can be obtained (N is an integer of 1 or more). From the viewpoint of mass production of cells, the lower limit of the number of passages N is preferably, for example, 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, or 9 or more. In addition, from the viewpoint of suppressing cell aging, the upper limit of the number of passages N is preferably, for example, 50 or less, 45 or less, 40 or less, 35 or less, 30 or less, 25 or less, or 20 or less.
[0057] The mesenchymal stem cells having relatively high proliferation potential selected by the above-mentioned method of the present invention are characterized in that they are CD106 negative and have an increased expression level of metallothionein family genes compared to the cells before the treatment with the physical or chemical stimulus. The characteristics of the mesenchymal stem cells having relatively high proliferation potential will be described later in this specification.
[0058] [3] Characteristics of mesenchymal stem cells in the present invention The mesenchymal stem cells of the present invention are characterized by being CD106 negative and having a higher expression level of metallothionein family genes than the cells before treatment with physical or chemical stimuli. Therefore, the mesenchymal stem cells of the present invention (mesenchymal stem cells with relatively high proliferation ability) are mesenchymal stem cells that are CD106 negative and have a higher expression level of metallothionein family genes than the cells before treatment with physical or chemical stimuli.
[0059] In the present invention, the expression marker of MSCs can be detected by any detection method known in the art. The expression marker includes, but is not limited to, cell surface antigens or intracellularly expressed proteins. Specific examples of the expression marker include CD106 (VCAM1), CD105 (Endoglin), CD73 (Ecto-5'-nucleotidase), CD90 (Thy-1), CD45 (Leukocyte Common Antigen), CD34 (Hematopoietic Progenitor Cell Antigen), CD11b (Integrin αM), CD79alpha (Mb-1), HLA-DR (Human Leukocyte Antigen DR), CD324 (E-cadherin) and CD326 (EpCAM).
[0060] The mesenchymal stem cells of the present invention are CD106 negative. The mesenchymal stem cells of the present invention are preferably CD105 positive, CD73 positive, CD90 positive, CD45 negative, CD34 negative, CD11b negative, CD79alpha negative, and HLA-DR negative.
[0061] The above-mentioned expression markers can be detected by, but are not limited to, flow cytometry or cell staining. In flow cytometry using a fluorescently labeled antibody, if a cell is detected that emits stronger fluorescence than a negative control (isotype control), the cell is judged to be "positive" for the marker. The fluorescently labeled antibody can be any antibody known in the art, and includes, but is not limited to, antibodies labeled with fluorescein isothiocyanate (FITC), phycoerythrin (PE), allophycocyanin (APC), etc. In cell staining, if a colored or fluorescent cell is observed under a microscope, the cell is judged to be "positive" for the marker. The cell staining may be immune cell staining using an antibody, or non-immune cell staining using no antibody.
[0062] The timing for detecting the above-mentioned expression markers is not particularly limited, but examples include before treatment with physical or chemical stimuli (e.g., immediately after isolating cells from a biological sample, immediately after pre-culture, immediately before a selection step, etc.), after treatment with physical or chemical stimuli (e.g., immediately after a selection step, immediately after main culture, immediately after N-th subculture after main culture (N is an integer of 1 or more), etc.), or before formulation into a pharmaceutical composition.
[0063] The mesenchymal stem cells of the present invention are preferably SA-β-Gal (senescence-associated beta-galactosidase) negative. As shown in the Examples below, the present inventors have found that MSCs with relatively low proliferation capacity are SA-β-Gal positive senescent cells, whereas MSCs with relatively high proliferation capacity are SA-β-Gal negative non-senescent cells. MSCs being SA-β-Gal negative means that the cells are MSCs with relatively high proliferation capacity.
[0064] The detection of SA-β-Gal described above can be carried out, for example, by detecting the activity of SA-β-Gal, specifically, by cell staining using an SA-β-Gal-specific substrate (e.g., a chromogenic or fluorescent substrate). When cells with stained cytoplasm are observed under an optical microscope in cell staining using an SA-β-Gal-specific substrate, the cells are judged to be "positive" for SA-β-Gal.
[0065] The timing of detecting the above-mentioned SA-β-Gal is not particularly limited, but may include, for example, before treatment with physical or chemical stimuli (e.g., immediately after isolating cells from a biological sample, immediately after pre-culture, immediately before a selection step, etc.), after treatment with physical or chemical stimuli (e.g., immediately after a selection step, immediately after main culture, immediately after Nth subculture after main culture (N is an integer of 1 or more), etc.), or before formulation into a pharmaceutical composition.
[0066] In the mesenchymal stem cells of the present invention, the expression level of metallothionein family genes is increased compared to cells before treatment with physical or chemical stimuli. Metallothionein is a low molecular weight (about 6,500) metal-binding protein containing many cysteine residues, and its presence has been confirmed in many biological species, with four subtypes in mammals (MT-I, MT-II, MT-III, MT-IV). The physiological functions of metallothionein-I and -II are known to be reduction of toxicity of heavy metals, accumulation of heavy metals, metabolic regulation of zinc and copper, antioxidant effect, scavenging effect against free radicals, reduction of side effects of anticancer drugs, and resistance to anticancer drugs. In the present invention, the expression level of metallothionein family genes is increased through treatment with physical or chemical stimuli, specifically, for example, freeze-thaw treatment, so that it is presumed that the proliferation of mesenchymal stem cells and the resistance to freeze-thaw of mesenchymal stem cells are improved, but the present invention is not limited by the above theory or mechanism.
[0067] Preferably, the metallothionein family genes include at least one, at least two, at least three, at least four, at least five, or all six selected from the group consisting of MT1E, MT1F, MT1G, MT1H, MT1X, and MT2A.
[0068] MT1E is a gene consisting of the base sequence shown in SEQ ID NO:1, or a gene encoding a polypeptide consisting of the amino acid sequence shown in SEQ ID NO:7.
[0069] MT1F is a gene consisting of the base sequence shown in SEQ ID NO:2, or a gene encoding a polypeptide consisting of the amino acid sequence shown in SEQ ID NO:8.
[0070] MT1G is a gene consisting of the base sequence shown in SEQ ID NO:3, or a gene encoding a polypeptide consisting of the amino acid sequence shown in SEQ ID NO:9.
[0071] MT1H is a gene consisting of the base sequence shown in SEQ ID NO:4, or a gene encoding a polypeptide consisting of the amino acid sequence shown in SEQ ID NO:10.
[0072] MT1X is a gene consisting of the base sequence shown in SEQ ID NO:5, or a gene encoding a polypeptide consisting of the amino acid sequence shown in SEQ ID NO:11.
[0073] MT2A is a gene consisting of the base sequence shown in SEQ ID NO:6, or a gene encoding a polypeptide consisting of the amino acid sequence shown in SEQ ID NO:12.
[0074] In the mesenchymal stem cells of the present invention, the expression level of metallothionein family genes is increased compared to the cells before treatment with physical or chemical stimuli, but is not particularly limited thereto, and is preferably increased by 1.1 times or more, 1.2 times or more, 1.3 times or more, 1.4 times or more, 1.5 times or more, 1.6 times or more, 1.7 times or more, 1.8 times or more, 1.9 times or more, 2.0 times or more, 2.1 times or more, or 2.2 times or more. The expression level of metallothionein family genes referred to here may be measured by any of the methods described below or by other methods, and the measurement method is not particularly limited.
[0075] The expression level of the above-mentioned metallothionein family gene can be measured using the transcription product (mRNA) of the metallothionein family gene or the metallothionein family protein as an indicator. Specifically, the expression level of the metallothionein family gene can be measured by RT-PCR, Northern blot hybridization, microarray analysis in which hybridization is performed on a microarray, or immunoassay (e.g., ELISA (enzyme-linked immunosorbent assay)).
[0076] Specifically, the above-mentioned microarray analysis in which hybridization is performed on a microarray can be carried out according to the following steps (1) to (4). (1) Adherent cells are non-enzymatically detached from the plastic culture vessel using a cell scraper (Corning) and collected by centrifugation. After stably preserving the cells using an RNA stabilization reagent (RNAlater (Thermo Fisher Scientific)), total RNA is extracted and purified using an RNA extraction kit (RNeasy Plus Mini kit (QIAGEN)). (2) cDNA is synthesized by reverse transcription using the purified total RNA as a template, and the synthesized cDNA is then transcribed into cRNA by in vitro transcription and labeled with biotin. (3) Biotin-labeled cRNA was added to the hybridization buffer and hybridized on the Human GeneGenome U133A 2.0 Array (Affymetrix) for 16 hours. After washing with the GeneChip Fluidics Station 450 (Affymetrix), phycoerythrin staining was performed, followed by scanning with the GeneChip Scanner 3000 7G (Affymetrix), image analysis with AGCC (Affymetrix GeneChip Command Console Software) (Affymetrix), and quantification with the Affymetrix Expression Console (Affymetrix). (4) The numerical data files for the two arrays are compared and analyzed using the analysis software GeneSpring GX (Agilent Technologies). The fold change value is calculated by dividing the normalized value of the mesenchymal stem cell sample by the normalized value of the cell sample (control) before treatment with physical or chemical stimuli.
[0077] As will be described in detail in the Examples, the mesenchymal stem cells of the present invention have improved resistance to freezing and thawing compared to cells before treatment with physical or chemical stimuli. The resistance to freezing and thawing can be evaluated, for example, using the survival rate of cells after cryopreservation and thawing as an indicator. Specifically, the resistance to freezing and thawing can be evaluated by leaving the cells after cryopreservation and thawing at a predetermined temperature (e.g., 25°C (room temperature), 37°C (body temperature)) for a predetermined time (e.g., 0, 1 or 2 hours), staining with trypan blue, and measuring the cell survival rate using a hemocytometer, but is not limited thereto.
[0078] The present inventors have found that the average diameter of MSCs in a suspended state with relatively high proliferation ability may be smaller than the average diameter of MSCs in a suspended state with relatively low proliferation ability. The method for measuring the diameter of MSCs in a suspended state is not particularly limited, but for example, it can be measured under a phase contrast microscope or can be measured using an automatic cell counter. The average diameter of MSCs in a suspended state is calculated as the average value of the diameters of multiple cells measured by the above measurement method.
[0079] In the present invention, the diameter of MSCs with relatively high proliferation potential in a suspended state may be, for example, but is not limited to, 80% or less, 75% or less, 70% or less, or 65% or less of the average diameter of MSCs with relatively low proliferation potential in a suspended state. Also, the average diameter of MSCs with relatively high proliferation potential in a suspended state may be, for example, but is not limited to, 45% or more, 50% or more, or 55% or more of the diameter of MSCs with relatively low proliferation potential in a suspended state.
[0080] The average diameter of MSCs with relatively high proliferation potential in the present invention in a suspended state may be, for example, but is not limited to, 28 μm or less, 27 μm or less, 26 μm or less, 25 μm or less, 24 μm or less, 23 μm or less, 22 μm or less, 21 μm or less, 20 μm or less, 19 μm or less, 18 μm or less, 17 μm or less, 16 μm or less, 15 μm or less, or 14 μm or less. The average diameter of MSCs with relatively high proliferation potential in a suspended state may be, for example, but is not limited to, 8 μm or more, 9 μm or more, or 10 μm or more.
[0081] The present inventors have found that the average length of the long axis of MSCs with relatively high proliferation ability in an adherent state may tend to be smaller than the average length of the long axis of MSCs with relatively low proliferation ability in an adherent state, but this is not particularly limited. The present inventors have also found that the average length of the short axis of MSCs with relatively high proliferation ability in an adherent state may tend to be smaller than the average length of the short axis of MSCs with relatively low proliferation ability in an adherent state, but this is not particularly limited. The method for measuring the length of the long axis or short axis of MSCs in an adherent state is not particularly limited, but can be measured, for example, by microscopic observation of cells adhered to a plastic culture vessel. The average length of the long axis or short axis of MSCs in an adherent state is calculated as the average length of the long axis or short axis of multiple cells measured by the above measurement method.
[0082] In the present invention, the average length of the long axis of MSCs with relatively high proliferation ability in an adherent state may be, for example, but is not limited to, 80% or less, 70% or less, 60% or less, 50% or less, or 40% or less of the average length of the long axis of MSCs with relatively low proliferation ability in an adherent state. Also, the average length of the long axis of MSCs with relatively high proliferation ability in an adherent state may be, for example, but is not limited to, 20% or more, 25% or more, 30% or more, or 35% or more of the average length of the long axis of MSCs with relatively low proliferation ability in an adherent state.
[0083] The average length of the long axis of the MSCs with relatively high proliferation potential in the present invention in an adherent state may be, for example, but is not limited to, 13 μm or more, 14 μm or more, 15 μm or more, or 16 μm or more. The average length of the long axis of the MSCs with relatively high proliferation potential in an adherent state may be, for example, but is not limited to, 48 μm or less, 46 μm or less, or 44 μm or less.
[0084] In the present invention, the average length of the short axis of MSCs with relatively high proliferation ability in an adherent state may be, for example, but is not limited to, 80% or less, 70% or less, 60% or less, 50% or less, or 40% or less of the average length of the short axis of MSCs with relatively low proliferation ability in an adherent state. Also, the average length of the short axis of MSCs with relatively high proliferation ability in an adherent state may be, for example, but is not limited to, 25% or more, 30% or more, or 35% or more of the average length of the short axis of MSCs with relatively low proliferation ability in an adherent state.
[0085] The average length of the short axis of the MSCs with relatively high proliferation potential in the present invention in an adherent state may be, for example, but is not limited to, 4 μm or more, 5 μm or more, or 6 μm or more. The average length of the short axis of the MSCs with relatively high proliferation potential in an adherent state may be, for example, but is not limited to, 14 μm or less, 13 μm or less, or 12 μm or less.
[0086] The present inventors have found that the specific proliferation rate of MSCs with relatively high proliferation capacity is higher than that of MSCs with relatively low proliferation capacity. That is, MSCs with relatively high proliferation capacity have a relatively high specific proliferation rate, and MSCs with relatively low proliferation capacity have a relatively low specific proliferation rate. The proliferation capacity of MSCs can be evaluated using the specific proliferation rate. The specific proliferation rate is defined as the increase in the number of cells per unit time, and is expressed as the specific proliferation rate: μ = ln (mt2 / mt1) / (t2-t1). Here, t1 and t2 are the number of days of culture, mt1 is the number of cells on day t1, and mt2 is the number of cells on day t2 (where t2>t1). Therefore, the unit of the specific proliferation rate is (cells / cells / day) = (1 / day).
[0087] In the present invention, the specific proliferation rate of MSCs with relatively high proliferation potential is preferably 1.1 times or more, more preferably 1.2 times or more, even more preferably 1.3 times or more, even more preferably 1.4 times or more, even more preferably 1.5 times or more, even more preferably 1.6 times or more, even more preferably 1.7 times or more, even more preferably 1.8 times or more, even more preferably 1.9 times or more, even more preferably 2.0 times or more, even more preferably 2.1 times or more, and even more preferably Preferably, it is 2.2 times or more, more preferably 2.3 times or more, more preferably 2.4 times or more, more preferably 2.5 times or more, more preferably 2.6 times or more, more preferably 2.7 times or more, more preferably 2.8 times or more, more preferably 2.9 times or more, more preferably 3.0 times or more, more preferably 3.1 times or more, more preferably 3.2 times or more, more preferably 3.3 times or more, more preferably 3.4 times or more, and particularly preferably 3.5 times or more. The specific proliferation rate of MSCs with relatively high proliferation potential is not particularly limited, and is, for example, 5.0 times or less, 4.5 times or less, or 4.0 times or less of the specific proliferation rate of MSCs with relatively low proliferation potential.
[0088] The specific proliferation rate of MSCs having relatively high proliferation ability in the present invention is 0.07 (1 / day) or more, preferably 0.08 (1 / day) or more, more preferably 0.09 (1 / day) or more, even more preferably 0.10 (1 / day) or more, even more preferably 0.11 (1 / day) or more, even more preferably 0.12 (1 / day) or more, even more preferably 0.13 (1 / day) or more, even more preferably 0.14 (1 / day) or more, even more preferably 0.15 (1 / day) or more, even more preferably 0.16 (1 / day) or more, even more preferably 0.17 (1 / day) or more, even more preferably 0.18 (1 / day) or more, even more preferably 0.19 (1 / day) or more, even more preferably 0.20 (1 / day) or more, even more preferably 0.21 (1 / day) or more, even more preferably 0.22 (1 / day) or more, and even more preferably Preferably, it is 0.23 (1 / day) or more, more preferably 0.24 (1 / day) or more, even more preferably 0.25 (1 / day) or more, even more preferably 0.26 (1 / day) or more, even more preferably 0.27 (1 / day) or more, even more preferably 0.28 (1 / day) or more, even more preferably 0.29 (1 / day) or more, even more preferably 0.30 (1 / day) or more, even more preferably 0.31 (1 / day) or more, even more preferably 0.32 (1 / day) or more, even more preferably 0.33 (1 / day) or more, even more preferably 0.34 (1 / day) or more, even more preferably 0.35 (1 / day) or more, even more preferably 0.36 (1 / day) or more, even more preferably 0.37 (1 / day) or more, even more preferably 0.38 (1 / day) or more, and particularly preferably 0.39 (1 / day) or more. Furthermore, the specific proliferation rate of MSCs with relatively high proliferation ability is not particularly limited, but is, for example, 0.60 (1 / day) or less or 0.50 (1 / day) or less.
[0089] The number of times that MSCs with relatively high proliferation ability in the present invention can be passaged is 1 or more, preferably 2 or more, more preferably 3 or more, even more preferably 4 or more, even more preferably 5 or more, even more preferably 6 or more, even more preferably 7 or more, even more preferably 8 or more, even more preferably 9 or more, even more preferably 10 or more, even more preferably 11 or more, even more preferably 12 or more, even more preferably 13 or more, even more preferably 14 or more, even more preferably 15 or more, even more preferably 16 or more, even more preferably 17 or more, even more preferably 18 or more, even more preferably 19 or more, even more preferably 20 or more, and even more preferably 25 or more. The upper limit of the number of times that the MSCs can be passaged is not particularly limited, and is, for example, 50 or less, 45 or less, 40 or less, 35 or less, or 30 or less.
[0090] According to the production method of the present invention, MSCs with relatively high proliferation ability can be obtained, which allows rapid mass production of cell preparations (pharmaceutical compositions). The lower limit of the number of cells obtained per culture batch (the number of cells obtained per unit surface area and per unit number of culture days) varies depending on the number of cells seeded, the seeding density, etc., but is, for example, 2.3 × 10 3 (pcs / cm 2 / day) or more, 2.4×10 3 (pcs / cm 2 / day) or more, 2.5×10 3 (pcs / cm 2 / day) or more, 2.6×10 3 (pcs / cm 2 / day) or more, 2.7×10 3 (pcs / cm 2 / day) or more, 2.8×10 3 (pcs / cm 2 / day) or more, 2.9×10 3 (pcs / cm 2 / day) or more, 3.0×10 3 (pcs / cm 2 / day) or more, 3.1×10 3 (pcs / cm 2 / day) or more or 3.2×10 3 (pcs / cm 2The upper limit of the number of cells obtained per culture batch is not particularly limited, but is, for example, 4.0 × 10 3 (pcs / cm 2 / day) or less, 3.9×10 3 (pcs / cm 2 / day) or less, 3.8×10 3 (pcs / cm 2 / day) or less, 3.7×10 3 (pcs / cm 2 / day) or less, 3.6×10 3 (pcs / cm 2 / day) or less, 3.5×10 3 (pcs / cm 2 / day) or less, 3.4×10 3 (pcs / cm 2 / day) or less or 3.3×10 3 (pcs / cm 2 / day).
[0091] The mesenchymal stem cells of the present invention may be provided as a composition in combination with a medium. The medium is preferably a liquid medium (e.g., a culture medium or a pharma- ceutically acceptable medium described below).
[0092] [4] Cell population containing mesenchymal stem cells According to the present invention, there is provided a cell population comprising mesenchymal stem cells, wherein the mesenchymal stem cells have increased expression levels of metallothionein family genes compared to cells prior to treatment with physical or chemical stimulation, and are CD106 negative.
[0093] In the cell population, the proportion of mesenchymal stem cells that are CD106 positive is preferably less than 5%, more preferably less than 4%, even more preferably less than 3%, even more preferably less than 2%, even more preferably less than 1%, and may be 0%.
[0094] In the cell population, the ratio of CD106-negative mesenchymal stem cells is preferably 95% or more, more preferably 96% or more, even more preferably 97% or more, even more preferably 98% or more, even more preferably 99% or more, and may be 100%.
[0095] The cell population of the present invention may contain at least CD90-positive mesenchymal stem cells. In the cell population, the ratio of CD90-positive mesenchymal stem cells is preferably 70% or more, more preferably 75% or more, even more preferably 80% or more, even more preferably 90% or more, even more preferably 91% or more, even more preferably 92% or more, even more preferably 93% or more, even more preferably 94% or more, even more preferably 95% or more, even more preferably 96% or more, even more preferably 97% or more, even more preferably 98% or more, even more preferably 99% or more, or may be 100%.
[0096] The cell population of the present invention may contain at least CD73-positive mesenchymal stem cells. In the cell population, the ratio of CD73-positive mesenchymal stem cells is preferably 55% or more, more preferably 60% or more, even more preferably 65% or more, even more preferably 70% or more, even more preferably 75% or more, even more preferably 80% or more, even more preferably 85% or more, even more preferably 90% or more, even more preferably 95% or more, even more preferably 96% or more, even more preferably 97% or more, even more preferably 98% or more, even more preferably 99% or more, or may be 100%.
[0097] Methods for measuring the proportion of cells positive for the above expression markers in the cell population include, but are not limited to, flow cytometry. When a cell is detected that emits stronger fluorescence compared to a negative control (isotype control) in flow cytometry using a fluorescently labeled antibody, the cell is determined to be "positive" for the marker. The proportion of mesenchymal stem cells positive for a particular expression marker in a cell population can be calculated by the following steps (1) to (3). (1) The measurement results are displayed in a histogram with the number of cells on the vertical axis and the fluorescence intensity of the dye labeled to the antibody on the horizontal axis. (2) Determine the fluorescence intensity at which the cell population with stronger fluorescence intensity accounts for 0.1 to 1.0% of the total cells measured using the isotype control antibody. (3) Among the total cells measured with an antibody against a specific expression marker, the percentage of cells with a higher fluorescence intensity than that determined in (2) above is calculated. Any fluorescently labeled antibody known in the art can be used, and examples thereof include, but are not limited to, antibodies labeled with fluorescein isothiocyanate (FITC), phycoerythrin (PE), allophycocyanin (APC), and the like. In addition, other methods for measuring the proportion of cells positive for the above expression markers in the cell population include, but are not limited to, cell staining. In cell staining, when a colored or fluorescent cell is observed under a microscope, the cell is determined to be "positive" for the marker. The proportion of cells positive for a specific expression marker in the cell population can be determined by observing the cell population at the same magnification using a microscope and determining the ratio of the number of positive cells to the total number of cells in the field of view. The cell staining may be immune cell staining using an antibody, or non-immune cell staining using no antibody.
[0098] The MSCs with relatively high proliferation capacity in the cell population of the present invention are preferably SA-β-Gal (senescence-associated beta-galactosidase) negative. As shown in the Examples below, the present inventors have found that MSCs with relatively low proliferation capacity are SA-β-Gal positive senescent cells, whereas MSCs with relatively high proliferation capacity are SA-β-Gal negative non-senescent cells. MSCs being SA-β-Gal negative means that the cells are MSCs with relatively high proliferation capacity.
[0099] In the cell population, the average proportion of SA-β-Gal-negative mesenchymal stem cells is preferably 90% or more, more preferably 91% or more, even more preferably 92% or more, even more preferably 93% or more, even more preferably 94% or more, even more preferably 95% or more, even more preferably 96% or more, even more preferably 97% or more, even more preferably 98% or more, even more preferably 99% or more, even more preferably 99.5% or more, or may be 100%.
[0100] The average proportion of cells positive for the above-mentioned SA-β-Gal in the cell population can be measured, for example, by detecting the activity of SA-β-Gal, specifically, by cell staining using an SA-β-Gal-specific substrate (e.g., a chromogenic or fluorescent substrate). When cells stained within the cytoplasm are observed under an optical microscope in cell staining using an SA-β-Gal-specific substrate, the cells are determined to be "positive" for SA-β-Gal. The average proportion of SA-β-Gal-negative cells in the cell population (the arithmetic mean of the proportion of SA-β-Gal-negative cells in the cell population) is calculated by the following steps (1) to (4). (1) A cell population adherent to a plastic culture vessel is prepared and stained with a SA-β-Gal specific substrate. (2) After cell staining, at least three locations on the same plastic culture vessel are observed under an optical microscope at the same magnification to determine the total cell number and the number of SA-β-Gal positive cells within the field of view. (3) For each measurement point, calculate the proportion of SA-β-Gal negative cells in the cell population using the following formula. Proportion of SA-β-Gal negative cells in a cell population = 100-{(number of SA-β-Gal positive cells / total number of cells) x 100(%)} (4) The average proportion of SA-β-Gal negative cells in the cell population (the arithmetic mean of the proportion of SA-β-Gal negative cells in the cell population) is calculated.
[0101] The mesenchymal stem cells in the cell population of the present invention are not particularly limited as long as they have an increased expression level of metallothionein family genes compared to the cells before treatment with physical or chemical stimulation, but it is preferable that the expression level is increased by 1.1-fold or more, 1.2-fold or more, 1.3-fold or more, 1.4-fold or more, 1.5-fold or more, 1.6-fold or more, 1.7-fold or more, 1.8-fold or more, 1.9-fold or more, 2.0-fold or more, 2.1-fold or more, or 2.2-fold or more.
[0102] In the cell population, the expression level of the above-mentioned metallothionein family gene can be measured using the transcription product (mRNA) of the metallothionein family gene or the metallothionein family protein as an indicator. Specifically, the expression level of the metallothionein family gene can be measured by RT-PCR, Northern blot hybridization, microarray analysis in which hybridization is performed on a microarray, or immunoassay (e.g., ELISA (enzyme-linked immunosorbent assay)).
[0103] Specifically, the above-mentioned microarray analysis in which hybridization is performed on a microarray can be carried out according to the following steps (1) to (4). (1) The adherent cell population is non-enzymatically detached from the plastic culture vessel using a cell scraper (Corning) and collected by centrifugation. The cell population is stably preserved using an RNA stabilization reagent (RNAlater (Thermo Fisher Scientific)), and total RNA is extracted and purified using an RNA extraction kit (RNeasy Plus Mini kit (QIAGEN)). (2) cDNA is synthesized by reverse transcription using the purified total RNA as a template, and the synthesized cDNA is then transcribed into cRNA by in vitro transcription and labeled with biotin. (3) Biotin-labeled cRNA was added to the hybridization buffer and hybridized on the Human GeneGenome U133A 2.0 Array (Affymetrix) for 16 hours. After washing with the GeneChip Fluidics Station 450 (Affymetrix), phycoerythrin staining was performed, followed by scanning with the GeneChip Scanner 3000 7G (Affymetrix), image analysis with AGCC (Affymetrix GeneChip Command Console Software) (Affymetrix), and quantification with the Affymetrix Expression Console (Affymetrix). (4) The numerical data files for the two arrays are compared and analyzed using the analysis software GeneSpring GX (Agilent Technologies). The fold change value is calculated by dividing the normalized value of the mesenchymal stem cell sample by the normalized value of the cell sample (control) before treatment with physical or chemical stimuli.
[0104] Preferably, the mesenchymal stem cells in the cell population of the present invention have improved resistance to freezing and thawing compared to the cells before treatment with physical or chemical stimuli. The resistance to freezing and thawing can be evaluated, for example, using the survival rate of cells after cryopreservation and thawing as an index. Specifically, the resistance to freezing and thawing can be evaluated by leaving the cells after cryopreservation and thawing at a predetermined temperature (e.g., 25°C (room temperature), 37°C (body temperature)) for a predetermined time (e.g., 0, 1 or 2 hours), staining with trypan blue, and measuring the cell survival rate using a hemocytometer, but is not limited thereto.
[0105] The present inventors have found that the average diameter of MSCs in a suspended state with relatively high proliferation ability may be smaller than the average diameter of MSCs in a suspended state with relatively low proliferation ability. The method for measuring the diameter of MSCs in a suspended state is not particularly limited, but for example, it can be measured under a phase contrast microscope or can be measured using an automatic cell counter. The average diameter of MSCs in a suspended state is calculated as the average value of the diameters of multiple cells measured by the above measurement method.
[0106] The average diameter of MSCs with relatively high proliferation ability in the mesenchymal stem cell population of the present invention in a suspended state may be, for example, but is not limited to, 28 μm or less, 27 μm or less, 26 μm or less, 25 μm or less, 24 μm or less, 23 μm or less, 22 μm or less, 21 μm or less, 20 μm or less, 19 μm or less, 18 μm or less, 17 μm or less, 16 μm or less, 15 μm or less, or 14 μm or less. The average diameter of MSCs with relatively high proliferation ability in a suspended state may be, for example, but is not limited to, 8 μm or more, 9 μm or more, or 10 μm or more.
[0107] The present inventors have found that the average length of the long axis of MSCs with relatively high proliferation ability in an adherent state may tend to be smaller than the average length of the long axis of MSCs with relatively low proliferation ability in an adherent state. The present inventors have also found that the average length of the short axis of MSCs with relatively high proliferation ability in an adherent state may tend to be smaller than the average length of the short axis of MSCs with relatively low proliferation ability in an adherent state. The method for measuring the length of the long axis or short axis of MSCs in an adherent state is not particularly limited, and can be measured, for example, by microscopic observation of cells adhered to a plastic culture vessel. The average length of the long axis or short axis of MSCs in an adherent state is calculated as the average length of the long axis or short axis of multiple cells measured by the above measurement method.
[0108] The average length of the long axis of MSCs with relatively high proliferation potential in the cell population of the present invention in an adherent state may be, for example, but is not limited to, 13 μm or more, 14 μm or more, 15 μm or more, or 16 μm or more. The average length of the long axis of MSCs with relatively high proliferation potential in an adherent state may be, for example, but is not limited to, 48 μm or less, 46 μm or less, or 44 μm or less.
[0109] The average short axis length of MSCs with relatively high proliferation potential in the cell population of the present invention in an adherent state may be, for example, but is not limited to, 80% or less, 70% or less, 60% or less, 50% or less, or 40% or less of the average short axis length of MSCs with relatively low proliferation potential in an adherent state. Also, the average short axis length of MSCs with relatively high proliferation potential in an adherent state may be, for example, but is not limited to, 25% or more, 30% or more, or 35% or more of the average short axis length of MSCs with relatively low proliferation potential in an adherent state.
[0110] The average length of the short axis of the MSCs with relatively high proliferation ability in the mesenchymal stem cell population of the present invention in an adherent state may be, for example, but is not limited to, 4 μm or more, 5 μm or more, or 6 μm or more. The average length of the short axis of the MSCs with relatively high proliferation ability in an adherent state may be, for example, but is not limited to, 14 μm or less, 13 μm or less, or 12 μm or less.
[0111] The present inventors have found that the specific proliferation rate of MSCs with relatively high proliferation potential in the cell population of the present invention is higher than that of MSCs with relatively low proliferation potential. That is, MSCs with relatively high proliferation potential in the cell population are MSCs with a relatively high specific proliferation rate, and MSCs with relatively low proliferation potential in the cell population are MSCs with a relatively low specific proliferation rate. The proliferation potential of MSCs in a cell population can be evaluated using the specific proliferation rate. The specific proliferation rate is defined as the increase in the number of cells per unit time, and is expressed as the specific proliferation rate: μ = ln (mt2 / mt1) / (t2-t1). Here, t1 and t2 are the number of days of culture, mt1 is the number of cells on day t1, and mt2 is the number of cells on day t2 (where t2>t1). Therefore, the unit of the specific proliferation rate is (cells / cells / day) = (1 / day).
[0112] The specific proliferation rate of MSCs with relatively high proliferation potential in the cell population of the present invention is preferably 1.1 times or more, more preferably 1.2 times or more, even more preferably 1.3 times or more, even more preferably 1.4 times or more, even more preferably 1.5 times or more, even more preferably 1.6 times or more, even more preferably 1.7 times or more, even more preferably 1.8 times or more, even more preferably 1.9 times or more, even more preferably 2.0 times or more, even more preferably 2.1 times or more, and More preferably, it is 2.2 times or more, more preferably 2.3 times or more, more preferably 2.4 times or more, more preferably 2.5 times or more, more preferably 2.6 times or more, more preferably 2.7 times or more, more preferably 2.8 times or more, more preferably 2.9 times or more, more preferably 3.0 times or more, more preferably 3.1 times or more, more preferably 3.2 times or more, more preferably 3.3 times or more, more preferably 3.4 times or more, and particularly preferably 3.5 times or more. The specific proliferation rate of MSCs with relatively high proliferation capacity is not particularly limited, and is, for example, 5.0 times or less, 4.5 times or less, or 4.0 times or less of the specific proliferation rate of MSCs with relatively low proliferation capacity.
[0113] The specific proliferation rate of MSCs with relatively high proliferation ability in the cell population of the present invention is 0.07 (1 / day) or more, preferably 0.08 (1 / day) or more, more preferably 0.09 (1 / day) or more, even more preferably 0.10 (1 / day) or more, even more preferably 0.11 (1 / day) or more, even more preferably 0.12 (1 / day) or more, even more preferably 0.13 (1 / day) or more, even more preferably 0.14 (1 / day) or more, even more preferably 0.15 (1 / day) or more, even more preferably 0.16 (1 / day) or more, even more preferably 0.17 (1 / day) or more, even more preferably 0.18 (1 / day) or more, even more preferably 0.19 (1 / day) or more, even more preferably 0.20 (1 / day) or more, even more preferably 0.21 (1 / day) or more, even more preferably 0.22 (1 / day) or more, More preferably, it is 0.23 (1 / day) or more, even more preferably 0.24 (1 / day) or more, even more preferably 0.25 (1 / day) or more, even more preferably 0.26 (1 / day) or more, even more preferably 0.27 (1 / day) or more, even more preferably 0.28 (1 / day) or more, even more preferably 0.29 (1 / day) or more, even more preferably 0.30 (1 / day) or more, even more preferably 0.31 (1 / day) or more, even more preferably 0.32 (1 / day) or more, even more preferably 0.33 (1 / day) or more, even more preferably 0.34 (1 / day) or more, even more preferably 0.35 (1 / day) or more, even more preferably 0.36 (1 / day) or more, even more preferably 0.37 (1 / day) or more, even more preferably 0.38 (1 / day) or more, and particularly preferably 0.39 (1 / day) or more. Furthermore, the specific proliferation rate of MSCs with relatively high proliferation ability is not particularly limited, but is, for example, 0.60 (1 / day) or less or 0.50 (1 / day) or less.
[0114] The number of times that MSCs with relatively high proliferation ability in the cell population of the present invention can be passaged is 1 or more, preferably 2 or more, more preferably 3 or more, even more preferably 4 or more, even more preferably 5 or more, even more preferably 6 or more, even more preferably 7 or more, even more preferably 8 or more, even more preferably 9 or more, even more preferably 10 or more, even more preferably 11 or more, even more preferably 12 or more, even more preferably 13 or more, even more preferably 14 or more, even more preferably 15 or more, even more preferably 16 or more, even more preferably 17 or more, even more preferably 18 or more, even more preferably 19 or more, even more preferably 20 or more, and even more preferably 25 or more. The upper limit of the number of times that the MSCs can be passaged is not particularly limited, and is, for example, 50 or less, 45 or less, 40 or less, 35 or less, or 30 or less.
[0115] The content of MSCs with relatively high proliferative ability in the cell population of the present invention is preferably 10% or more, more preferably 20% or more, even more preferably 30% or more, even more preferably 40% or more, even more preferably 50% or more, even more preferably 60% or more, even more preferably 70% or more, even more preferably 80% or more, even more preferably 90% or more, even more preferably 91% or more, even more preferably 92% or more, even more preferably 93% or more, even more preferably 94% or more, even more preferably 95% or more, even more preferably 96% or more, even more preferably 97% or more, even more preferably 98% or more, even more preferably 99% or more, and particularly preferably 100%.
[0116] The cell population of the present invention can be stored in a frozen state until immediately before use. The cell population of the present invention may contain any component other than MSCs with relatively high proliferation ability. Such components can include, but are not limited to, salts, polysaccharides (e.g., HES, dextran, etc.), proteins (e.g., albumin, etc.), DMSO, medium components (e.g., components contained in RPMI1640 medium, etc.).
[0117] The cell population of the present invention may be provided as a composition in combination with a medium. The medium may preferably be a liquid medium (e.g., a culture medium or a pharma- ceutically acceptable medium described below).
[0118] [5] Pharmaceutical composition The mesenchymal stem cells having relatively high proliferation ability according to the present invention, or a cell population containing the mesenchymal stem cells, can be used as a pharmaceutical composition. The pharmaceutical composition of the present invention is a pharmaceutical composition comprising the mesenchymal stem cells of the present invention or the cell population of the present invention and a pharma- ceutical acceptable medium.
[0119] The pharmaceutical composition of the present invention can be used as a cell therapy agent, for example, an agent for treating intractable diseases. The pharmaceutical composition of the present invention can be used as a therapeutic agent for a disease selected from immune-related diseases, ischemic diseases (lower limb ischemia, ischemic heart disease (myocardial infarction, etc.), coronary heart disease, cerebrovascular ischemia, renal ischemia, pulmonary ischemia, etc.), neurological diseases, graft-versus-host disease (GVHD), Crohn's disease, inflammatory bowel diseases including ulcerative colitis, collagen diseases including systemic lupus erythematosus, cerebral infarction, intracerebral hematoma, cerebrovascular palsy, radiation enteritis, liver cirrhosis, stroke, atopic dermatitis, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), scleroderma, diseases caused by degeneration and / or inflammation of connective tissues such as cartilage, eye diseases, angiogenesis-related diseases, congestive heart failure, cardiomyopathy, wounds, epithelial damage, fibrosis, lung diseases, and cancer. By administering the pharmaceutical composition of the present invention to the treatment site in an amount that allows the effect to be measured, inflammation can be suppressed.
[0120] The present invention further provides use of the mesenchymal stem cells or cell population of the present invention for the manufacture of a pharmaceutical composition. The present invention further provides the mesenchymal stem cell of the present invention or the cell population of the present invention for use in a pharmaceutical composition. The present invention further provides the mesenchymal stem cell of the present invention or the cell population of the present invention for use in the treatment of a disease selected from immune-related diseases, ischemic diseases (lower limb ischemia, ischemic heart disease (myocardial infarction, etc.), coronary heart disease, cerebrovascular ischemia, renal ischemia, pulmonary ischemia, etc.), neurological diseases, graft-versus-host disease (GVHD), Crohn's disease, inflammatory bowel diseases including ulcerative colitis, collagen diseases including systemic lupus erythematosus, cerebral infarction, intracerebral hematoma, cerebrovascular pleurisy, radiation enteritis, liver cirrhosis, stroke, atopic dermatitis, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), scleroderma, diseases caused by degeneration and / or inflammation of connective tissues such as cartilage, eye diseases, angiogenesis-related diseases, congestive heart failure, cardiomyopathy, wounds, epithelial damage, fibrosis, lung diseases, and cancer. The present invention further provides the mesenchymal stem cell of the present invention or the cell population of the present invention, which is administered to a patient or subject and used for myocardial regeneration, cardiomyocyte production, angiogenesis, vascular repair, or suppression of immune responses.
[0121] The present invention further provides a method for transplanting cells into a patient or subject, and a method for treating a disease in a patient or subject, comprising the step of administering to the patient or subject a therapeutically effective amount of the mesenchymal stem cells of the present invention or the cell population of the present invention.
[0122] The dosage of the pharmaceutical composition of the present invention is the amount of cells that, when administered to a patient or subject, can provide a therapeutic effect against a disease compared to a patient or subject not administered the composition. The specific dosage can be appropriately determined depending on the dosage form, administration method, purpose of use, and the age, weight, and symptoms of the patient or subject. The dosage is not particularly limited, but may be, for example, 10 4 pcs / kg body weight or more, 10 5 Pieces / kg body weight or more or 10 6 The dosage is not particularly limited, but may be, for example, 10 9 pieces / kg weight or less, 10 8 10 pieces / kg body weight or less 7per kg body weight or less.
[0123] The method of administration of the pharmaceutical composition of the present invention is not particularly limited, but examples thereof include subcutaneous injection, intralymph node injection, intravenous injection, intravenous drip injection, intraperitoneal injection, intrathoracic injection, or direct injection into a local area, or direct transplantation into a local area. Regarding the method of administration of the pharmaceutical composition, for example, JP 2015-61520 A, Onken JE, t al. American College of Gastroenterology Conference 2006 Las Vegas, NV, Abstract 121., Garcia-Olmo D, et al. Dis Colon Rectum 2005; 48: 1416-23., etc., disclose intravenous injection, intravenous drip injection, direct injection into a local area, direct transplantation into a local area, etc. The pharmaceutical composition of the present invention can also be administered by various methods described in the above-mentioned documents.
[0124] The pharmaceutical composition of the present invention can also be used as an injection preparation for the treatment of other diseases, or as a transplant preparation for a cell mass or a sheet-like structure, or as a gel preparation mixed with any gel.
[0125] The patient or subject of the present invention is typically a human, but may be another animal, such as, but not limited to, a mammal such as a dog, a cat, a cow, a horse, a pig, a goat, a sheep, a monkey (cynomolgus monkey, rhesus monkey, common marmoset, Japanese monkey), a ferret, a rabbit, a rodent (mouse, rat, gerbil, guinea pig, hamster), or a bird such as a chicken or a quail.
[0126] The pharmaceutical composition of the present invention can be stored in a frozen state until immediately before use.The pharmaceutical composition of the present invention may contain any component used in human treatment.Such components can include, but are not limited to, salts, polysaccharides (e.g., HES, dextran, etc.), proteins (e.g., albumin, etc.), DMSO, medium components (e.g., components contained in RPMI1640 medium, etc.).
[0127] The pharmaceutical composition of the present invention may also be a dilution of mesenchymal stem cells or cell populations with an infusion preparation used as a pharma- ceutical acceptable medium. The "infusion preparation (pharma-ceutical acceptable medium)" in this specification is not particularly limited as long as it is a solution used in human treatment, and examples thereof include physiological saline, 5% glucose solution, Ringer's solution, lactate Ringer's solution, acetate Ringer's solution, initiation solution (solution No. 1), dehydration replacement solution (solution No. 2), maintenance infusion solution (solution No. 3), postoperative recovery solution (solution No. 4), etc.
[0128] Regarding the medical use of stem cells such as mesenchymal stem cells, for example, see JP-T-2012-509087, JP-T-2014-501249, JP-A-2013-256515, JP-A-2014-185173, JP-A-2015-038059, JP-A-2015-110659, JP-T-2006-521121, JP-T-2009-542727, JP-T-2010-535715, JP-T-2014-224117, JP-T-2015-061 In Japanese Patent Publication No. 862, Japanese Translation of PCT International Publication No. 2002-511094, Japanese Translation of PCT International Publication No. 2004-507454, Japanese Translation of PCT International Publication No. 2010-505764, Japanese Translation of PCT International Publication No. 2011-514901, Japanese Patent Publication No. 2013-064003, Japanese Patent Publication No. 2015-131795, etc., treatment of immune-related diseases and disorders, angiogenesis, generation, repair and / or maintenance of connective tissue, treatment of eye diseases and excessive angiogenesis, myocardial regeneration, joint repair, treatment of genetic diseases and disorders, and immunoregulation are known. In addition, Japanese Translation of PCT International Publication No. 2010-518096 describes the treatment of inflammatory diseases using placental stem cells, and Japanese Patent Publication No. 2015-178498 and Japanese Patent No. 5950577 describe the treatment of stroke using placental stem cells. Furthermore, treatment of heart failure using bone marrow mesenchymal stem cells is described in J Am Coll Cardiol. 2009 December 8; 54(24): 2277-2286, treatment of cerebral infarction using bone marrow mesenchymal stem cells is described in Brain 2011: 134; 1790-1807, and treatment of heart failure using placental mesenchymal stem cells is described in Ann Thorac Surg, 2013; 95: 1827-33. The mesenchymal stem cells or cell population of the present invention are also useful for treating various diseases described in the above documents.
[0129] The present invention will be specifically described in the following examples, but the present invention is not limited to these examples. EXAMPLES
[0130] Example 1 Amniotic membrane MSCs with a high specific proliferation rate (amniotic membrane MSCs with relatively high proliferation potential) were obtained by the following series of steps 1-1 to 1-6.
[0131] (Step 1-1: Collection of amniotic membrane) Fetal appendages, the amniotic membrane and placenta, were collected aseptically from pregnant women undergoing elective cesarean section who had given informed consent. The obtained amniotic membrane and placenta were placed in a sterile tray containing physiological saline, and the amniotic membrane was manually peeled off from the stump of the amniotic membrane. The amniotic membrane was washed twice with Hanks' balanced salt solution (Ca·Mg-free) to remove any attached blood and blood clots.
[0132] (Step 1-2: Enzyme treatment of amniotic membrane and collection of amniotic membrane MSCs) (method) 5 mL of Hanks' balanced salt solution (containing Ca·Mg) containing 300 CDU / mL purified collagenase (Worthington, CLSPA) and 200 PU / mL dispase I (Wako Pure Chemical Industries, part number 386-02271) was added per 1 g of amniotic membrane, and the mixture was shaken at 60 rpm for 90 minutes at 37°C. Here, CDU (collagen digestion unit) is defined as the amount of enzyme that produces amino acids and peptides equivalent to 1 μmol of leucine at 37°C and pH 7.5 in 5 hours using collagen as a substrate. PU (protease unit) is defined as the amount of enzyme that produces amino acids and peptides equivalent to 1 μg of tyrosine at 35°C and pH 7.2 in 1 minute using lactate casein as a substrate. The enzyme-treated amniotic membrane was suspended in 2 volumes of αMEM (Alpha Modification of Minimum Essential Medium Eagle) containing 10% fetal bovine serum (FBS). The obtained cell suspension was filtered using a nylon mesh filter (pore size: 100 μm), and the filtrate containing amniotic membrane MSCs was collected. The undigested amniotic membrane remaining on the nylon mesh filter was evaluated by hematoxylin-eosin (HE) staining. The filtrate containing amniotic membrane MSCs was centrifuged at 400xg for 5 minutes, and the supernatant was removed. The obtained cell pellet was suspended in αMEM containing 10% FBS to obtain a cell suspension containing amniotic membrane MSCs with different proliferation abilities. A part of the obtained cell suspension was mixed with Turk's staining solution, and the cell number was measured. The amniotic membrane MSCs collected from the filtrate were stained with labeled antibodies for 15 minutes at 4°C, and then propidium iodide or 7-AAD (7-Amino-Actinomycin D) was added to remove dead cells, and the surface antigens were analyzed using a flow cytometer (FACSCanto: Becton, Dickinson and Company, BD Japan (hereinafter abbreviated as BD)). The labeled antibody used was anti-CD90-FITC antibody (BD).
[0133] (result) Hematoxylin-eosin (HE) staining revealed that the epithelial cell layer of the amniotic membrane remaining on the filter was not digested, and that many epithelial cells were present within the epithelial cell layer. In addition, the extracellular matrix layer of the amniotic membrane remaining on the filter was digested, and no amniotic MSCs were identified on the filter. This indicates that by using collagenase and dispase, which target the extracellular matrix layer of the amniotic membrane and not the epithelial cell layer of the amniotic membrane, a filtrate containing almost no epithelial cells was recovered.
[0134] The number of cells obtained from the amniotic tissue was 2.3 × 10 per gram of tissue weight by cell counting using Turk's staining. 6 It was confirmed that it was an individual.
[0135] Flow cytometry revealed that the cell population, including the cells recovered from the filtrate, was CD90 positive, indicating that the cells recovered from the filtrate were mesenchymal stem cells.
[0136] (Step 1-3: Preculture 1) A portion of the cell population obtained from the enzyme treatment of the amniotic membrane was seeded in a plastic culture vessel and cultured in αMEM containing 10% FBS until the confluence rate reached 90% to 95%. The cells obtained by this process are called preculture 1 cells.
[0137] (Step 1-4: Preculture 2) (method) The pre-cultured 1 cells were treated with ethylenediaminetetraacetic acid (EDTA) and then with trypsin to detach them from the plastic culture vessel. The obtained cell suspension was centrifuged and the supernatant was removed. The obtained cell pellet was suspended in αMEM containing 10% FBS. The seeding density was 2.8 × 10 3 pieces / cm 2 The cells were seeded in a plastic culture vessel so that the cells were in the same concentration as the control, and cultured in αMEM containing 10% FBS for 8 days. The cells obtained by this preculture are referred to as preculture 2 cells. The preculture 2 cells were used in the following tests.
[0138] (result) After 8 days of culture, preculture 2 cells were 4.6 × 10 3 pieces / cm 2 In this case, the specific growth rate of precultured 2 cells was 0.06 (1 / day).
[0139] (Steps 1-5: Stimulation of amniotic membrane MSCs by freezing and thawing) (method) The pre-cultured 2 cells were treated with EDTA and then with trypsin to detach them from the plastic culture vessel. The obtained cell suspension was centrifuged and the supernatant was removed. The obtained cell pellet was diluted to 2.0 × 10 in RPMI1640 medium containing 0.5% (w / v) human serum albumin (HSA) (Venesys, 25% donated blood albumin for intravenous injection 12.5 g / 50 mL). 7 The cells were suspended at a concentration of 12 cells / mL or less. A cryopreservation solution was prepared containing 12% (w / v) hydroxyethyl starch (HES) (Nipro, product number HES40), 10% (w / v) dimethyl sulfoxide (DMSO) (Sigma-Aldrich, product number D2650), and 8% (w / v) human serum albumin (HSA) (Venesys, donated blood albumin 25% intravenous injection 12.5 g / 50 mL). The cell suspension and the cryopreservation solution were mixed in equal amounts on ice, and 1 mL was transferred to a cryotube. Using a program freezer, the cryotube was cooled to -40°C at a rate of -2°C / min to -1°C / min, then cooled to -90°C at a rate of -10°C / min, and then frozen and stored in a -150°C ultra-low temperature freezer for 2 days. The cryotube that had been frozen and stored was immersed in a 37°C thermostatic bath and rapidly thawed. A portion of the thawed cell suspension was taken and stained with trypan blue, and the number, viability and size of the cells were measured using a hemocytometer.
[0140] (result) As shown in FIG. 1 and Table 1, the suspended amniotic MSCs immediately after the freeze-thaw process contained two types of cells (i.e., relatively large-sized cells and relatively small-sized cells), namely, a cell group with a diameter of 19.9±3.1 μm (i.e., average diameter 19.9 μm) and a cell group with a diameter of 12.0±1.9 μm (i.e., average diameter 12.0 μm). The cell viability immediately after the freeze-thaw process was 55%, and the content of relatively small-sized cells (among live cells), i.e., the ratio of the number of relatively small-sized cells / the number of relatively large-sized cells, was 2% (i.e., the number of relatively small-sized cells / the number of relatively large-sized cells=2 / 98). The cell viability of the cells subjected to the freeze-thaw treatment (pre-cultured 2 cells) was 91%, and the content of relatively small-sized cells (among the live cells) was 1% (i.e., the number of relatively small-sized cells / the number of relatively large-sized cells=1 / 99). The above results indicate that the survival rate of amniotic MSCs decreased due to freezing-thawing treatment, and that this decrease in survival rate was due to the death of relatively large cells (cells with a large diameter).
[0141] [Table 1]
[0142] (Step 1-6: Main culture) (method) The amniotic membrane MSCs after the freeze-thaw process were cultured as follows. The thawed cell suspension was centrifuged and the supernatant was removed. The obtained cell pellet was suspended in αMEM containing 10% FBS. A portion of the obtained cell suspension was seeded in a plastic culture vessel and cultured in αMEM containing 10% FBS until the confluence rate reached 90% to 95%. The cells obtained by this culture are referred to as main culture 1 cells. The adherent main culture 1 cells were treated with EDTA and then with trypsin to detach them from the plastic culture vessel. The obtained cell suspension was centrifuged and the supernatant was removed. The obtained cell pellet was suspended in αMEM containing 10% FBS. A portion of the obtained cell suspension was centrifuged at 6300 cm 2 The cells were seeded onto a plastic culture vessel with a total culture surface area of 100 mm and cultured in αMEM containing 10% FBS until the confluence rate reached 90% to 95%. The cells obtained by this subculture and culture are called passage 1 cells. The passage 1 cells were collected by EDTA-trypsin treatment and centrifugation. A portion of the cells from the first primary culture and the first passage were collected and stained with trypan blue, and the number and viability of the cells were measured using a hemocytometer. A cellular senescence assay was performed on the cells from the first primary culture and the first passage using a Cellular Senescence Detection Kit (SA-β-Gal Staining) (Cell Biolabs). A portion of the cells from the first primary culture and the first passage were collected and stained with a labeled antibody at 4°C for 15 minutes, after which propidium iodide or 7-AAD (7-Amino-Actinomycin D) was added to remove dead cells, and the surface antigens were analyzed using a flow cytometer (FACSCanto: BD). The labeled antibodies used were anti-CD90-FITC antibody (BD), anti-CD105-FITC antibody (Ancell), anti-CD73-PE antibody (BD), anti-CD106-PE antibody (Miltenyi Biotec), anti-CD324-PE antibody (BD), anti-CD326-FITC antibody (BD), anti-CD45-FITC antibody (BD), anti-CD34-PE antibody (BD) and anti-HLA-DR-FITC antibody (BD). The ratio of CD106-positive mesenchymal stem cells in the cell population was calculated by the following steps (1) to (3). (1) The measurement results were plotted in a histogram with the cell number on the vertical axis and the fluorescence intensity of the dye labeled to the antibody on the horizontal axis. (2) The fluorescence intensity at which the cell population with stronger fluorescence intensity accounted for 0.1 to 1.0% of the total cells measured using the isotype control antibody was determined. (3) Of the total cells measured with an antibody against CD106, the percentage of cells with a fluorescence intensity higher than that determined in (2) above was calculated.
[0143] (result) The cells after freeze-thawing (main culture 1 cells and passage 1 cells) took 10 and 11 days, respectively, to reach a confluence rate of 90% to 95%. In these cases, the specific proliferation rate of the main culture 1 cells was 0.20 (1 / day), and the specific proliferation rate of the passage 1 cells was 0.19 (1 / day) (Table 2). This demonstrated that the specific proliferation rate of the freeze-thawed amniotic membrane MSCs was very high. The above results indicate that amniotic membrane MSCs with a relatively small size are amniotic membrane MSCs with a high specific proliferation rate (i.e., amniotic membrane MSCs with a relatively high proliferation ability). In addition, the number of cells obtained from passage 1 cells was 2.0 × 10 8 This resulted in 2.9 × 10 3 (pcs / cm 2 It can be seen that 1000 cells (passage 1 cells) were obtained. The above results demonstrate that amniotic membrane MSCs necessary for cell pharmaceutical preparations can be prepared and produced in large quantities and quickly.
[0144] [Table 2]
[0145] Phase contrast microscopy images of the adhered amnion MSCs are shown in Figures 2, 3, and 4. Regardless of whether or not they were subjected to freeze-thaw treatment, the morphology of the adhered amnion MSCs was fibroblast-like spindle or small polygonal. In the case of amniotic MSCs (pre-cultured 2 cells) that had not been subjected to freeze-thaw treatment, almost all of the cells in the confluent state had a long axis length of 78.4 ± 25.3 μm (i.e., average long axis length 78.4 μm) and a short axis length of 22.8 ± 6.0 μm (i.e., average short axis length 22.8 μm) (cells with large long and short axes, i.e., relatively large size cells) (Table 3). As mentioned above, the content of relatively small size cells in these pre-cultured 2 cells was 1%. On the other hand, the cells cultured until confluent after the freeze-thaw treatment (main culture 1 cells) contained not only the relatively large cells mentioned above, but also cells with a major axis length of 30.1 ± 13.6 μm (i.e., average major axis length 30.1 μm) and a minor axis length of 8.7 ± 2.5 μm (i.e., average minor axis length 8.7 μm) (cells with small major and minor axes, i.e., relatively small sized cells) (Table 3). The content of relatively small sized cells in main culture 1 cells was 90% (i.e., number of relatively small sized cells / number of relatively large sized cells = 90 / 10), and the content of relatively small sized cells in passage 1 cells was 98% (i.e., number of relatively small sized cells / number of relatively large sized cells = 98 / 2). These results indicate that the proliferation rate (specific proliferation rate) of relatively large cells was significantly decreased by the freeze-thaw treatment, and therefore relatively large cells did not proliferate in culture, and mainly relatively small cells proliferated.
[0146] [Table 3]
[0147] To investigate the number of possible passages, the passage 1 cells were further passaged and cultured, and passage 17 cells (cells that had been passaged 17 times) were obtained. This indicates that the cells obtained after the freeze-thaw treatment can be passaged at least 17 times.
[0148] We performed a cell senescence assay (cell staining) of amnion MSCs using the senescence marker Senescence associated β-galactosidase (SA-β-Gal) as an index.The results showed that relatively large amnion MSCs (i.e., amnion MSCs with a low specific proliferation rate, i.e., amnion MSCs with a relatively low proliferation capacity) were SA-β-Gal positive senescent cells (Figure 5), whereas relatively small amnion MSCs (i.e., amnion MSCs with a high specific proliferation rate, i.e., amnion MSCs with a relatively high proliferation capacity) were SA-β-Gal negative non-senescent cells.
[0149] As a result of flow cytometry, CD90, CD105 and CD73 were all positive in the main culture 1 cells and the passage 1 cells, and CD106, CD324, CD326, CD45, CD34 and HLA-DR were all negative. The ratio of CD106 positive cells in the cell population containing the main culture 1 cells was 1.4%. On the other hand, the ratio of CD106 positive cells in the cell population containing the passage 1 cells was 0.0%. These indicate that the main culture 1 cells and the passage 1 cells are amniotic mesenchymal stem cells that contain almost no epithelial cells, blood cells or vascular endothelial cells. The obtained amniotic mesenchymal stem cells were viable cells suitable for cell formulation.
[0150] Example 2 Amniotic membrane MSCs with a high specific proliferation rate (amniotic membrane MSCs with relatively high proliferation potential) were obtained by the following series of steps 2-1 to 2-8.
[0151] (Step 2-1: Collection of amniotic membrane) Fetal appendages, the amniotic membrane and placenta, were collected aseptically from pregnant women undergoing elective cesarean section who had given informed consent. The obtained amniotic membrane and placenta were placed in a sterile tray containing physiological saline, and the amniotic membrane was manually peeled off from the stump of the amniotic membrane. The amniotic membrane was washed twice with Hanks' balanced salt solution (Ca·Mg-free) to remove any attached blood and blood clots.
[0152] (Step 2-2: Enzyme treatment of amniotic membrane and collection of amniotic membrane MSCs) 5 mL of Hanks' balanced salt solution (containing Ca·Mg) containing 300 CDU / mL purified collagenase and 200 PU / mL dispase I was added per gram of amniotic membrane, and the mixture was shaken at 60 rpm at 37°C for 90 minutes. The enzyme-treated amniotic membrane was suspended in 2 volumes of αMEM containing 10% FBS. The resulting cell suspension was filtered using a nylon mesh filter (pore size: 100 μm) to collect the filtrate containing amniotic membrane MSCs. The resulting filtrate was centrifuged at 400 x g for 5 minutes, and the supernatant was removed. The resulting cell pellet was suspended in αMEM containing 10% FBS to obtain a cell suspension.
[0153] (Step 2-3: Preculture 1) The cell population obtained from the enzyme treatment of the amniotic membrane was cultured at 1890 cm 2 The cells were seeded onto a plastic culture vessel of (total culture surface area) and cultured in αMEM containing 10% FBS until the confluence rate reached 90% to 95%.
[0154] (Step 2-4: Preculture 2) The adherent cells obtained in step 2-3 were treated with EDTA-trypsin to detach the cells from the plastic culture vessel. The obtained cell suspension was centrifuged and the supernatant was removed. The obtained cell pellet was suspended in αMEM containing 10% FBS. The total amount of the obtained cell suspension was diluted with 6300 cm 2 The cells were seeded onto a plastic culture vessel of (total culture surface area) and cultured in αMEM containing 10% FBS until the confluence rate reached 90% to 95%.
[0155] (Step 2-5: Preculture 3) The cells in an adherent state obtained in step 2-4 were treated with EDTA-trypsin to detach the cells from the plastic culture vessel. The obtained cell suspension was centrifuged and the supernatant was removed. The obtained cell pellet was suspended in αMEM containing 10% FBS. The total amount of the obtained cell suspension was added to 2.5 ml 2 The cells were seeded onto a plastic culture vessel of (total culture surface area) and cultured in αMEM containing 10% FBS until the confluence rate reached 90% to 95%.
[0156] (Step 2-6: Stimulation of amniotic membrane MSCs by freezing and thawing) The adherent cells obtained in step 2-5 were treated with EDTA-trypsin to detach the cells from the plastic culture vessel. The obtained cell suspension was centrifuged to remove the supernatant. The obtained cell pellet was diluted with 2.0 × 10 7 The cells were suspended at a concentration of 0.1 to 0.5 cells / mL or less. A cryopreservation solution containing 12% (w / v) HES, 10% (w / v) DMSO, and 8% (w / v) HSA was prepared. Equal amounts of the cell suspension and the cryopreservation solution were mixed on ice and dispensed into four freezing bags. Using a programmable freezer, the freezing bags were cooled to -40°C at a rate of -2°C / min to -1°C / min, then cooled to -90°C at a rate of -10°C / min, and then frozen and stored in a -150°C ultra-low temperature freezer for 14 days. One of the four frozen freezing bags was immersed in a 37°C incubator and rapidly thawed.
[0157] (Step 2-7: Main culture 1) (method) The thawed cell suspension (one freezing bag) obtained in step 2-6 was centrifuged and the supernatant was removed. The obtained cell pellet was suspended in αMEM containing 10% FBS. The total amount of the obtained cell suspension was added to 2.5 ml 2 (total culture surface area) plastic culture vessel and cultured in αMEM containing 10% FBS until the confluence rate reached 90% to 95%. Cells (cell populations containing amniotic membrane MSCs with a high specific proliferation rate, i.e., cell populations containing amniotic membrane MSCs with relatively high proliferation ability) were collected by EDTA-trypsin treatment and centrifugation.
[0158] (result) The number of cells obtained in steps 2-7 was 7.6 × 10 8 In this process, the number of culture days from seeding the cells to reaching a confluence rate of 90% to 95% was 10 days. From these results, it was found that 3.0 × 10 3(pcs / cm 2 It can be seen that amniotic membrane MSCs (100 / day) were obtained. The specific proliferation rate of the obtained cells was 0.14 (1 / day). Furthermore, the obtained amniotic membrane MSCs were viable cells suitable for cell formulation. These results demonstrate that it is possible to rapidly prepare and produce large quantities of amniotic membrane MSCs required for cell formulation.
[0159] (Step 2-8: Main culture 2) (method) The total amount of cells obtained in step 2-7 was 10.1 m 2 (total culture surface area) plastic culture vessel and cultured in αMEM containing 10% FBS until the confluence rate reached 90% to 95%. Cells (cell populations containing amniotic membrane MSCs with a high specific proliferation rate, i.e., cell populations containing amniotic membrane MSCs with relatively high proliferation ability) were collected by EDTA-trypsin treatment and centrifugation.
[0160] (result) The number of cells obtained in step 2-8 was 3.0 × 10 9 In this process, the number of culture days from seeding the cells to reaching a confluence rate of 90% to 95% was 9 days. From these results, it was found that 3.3 × 10 3 (pcs / cm 2 It can be seen that amniotic membrane MSCs (100 / day) were obtained. The specific proliferation rate of the obtained cells was 0.15 (1 / day). Furthermore, the obtained amniotic membrane MSCs were viable cells suitable for cell formulation. These results demonstrate that it is possible to rapidly prepare and produce large quantities of amniotic membrane MSCs required for cell formulation.
[0161] Example 3 Amniotic membrane MSCs with a high specific proliferation rate (amniotic membrane MSCs with relatively high proliferation potential) were obtained by the following series of steps 3-1 to 3-9.
[0162] (Step 3-1: Collection of amniotic membrane) Fetal appendages, the amniotic membrane and placenta, were collected aseptically from pregnant women undergoing elective cesarean section who had given informed consent. The obtained amniotic membrane and placenta were placed in a sterile tray containing physiological saline, and the amniotic membrane was manually peeled off from the stump of the amniotic membrane. The amniotic membrane was washed twice with Hanks' balanced salt solution (Ca·Mg-free) to remove any attached blood and blood clots.
[0163] (Step 3-2: Enzyme treatment of amniotic membrane and collection of amniotic membrane MSCs) (method) 5 mL of Hanks' balanced salt solution (containing Ca·Mg) containing 300 CDU / mL purified collagenase and 200 PU / mL dispase I was added per gram of amniotic membrane, and the mixture was shaken at 60 rpm at 37°C for 90 minutes. The enzyme-treated amniotic membrane was suspended in αMEM containing 10% FBS in a double volume. The resulting cell suspension was filtered using a nylon mesh filter (pore size: 100 μm) to recover the filtrate containing amniotic membrane MSCs. The undigested amniotic membrane remaining on the nylon mesh filter was evaluated by hematoxylin-eosin (HE) staining. The resulting filtrate was centrifuged at 400xg for 5 minutes, and the supernatant was removed. The resulting cell pellet was suspended in αMEM containing 10% FBS and 1× Antibiotic-Antimycotic (Thermo Fisher Scientific) to obtain a cell suspension. A portion of the resulting cell suspension was mixed with Turk's staining solution to measure the cell count. The amniotic membrane MSCs collected from the filtrate were stained with labeled antibodies for 15 minutes at 4°C, and then propidium iodide or 7-AAD (7-Amino-Actinomycin D) was added to remove dead cells, and surface antigens were analyzed using a flow cytometer (FACSCanto: Becton, Dickinson and Company, BD Japan (hereinafter abbreviated as BD)). Anti-CD90-FITC antibody (BD) was used as the labeled antibody.
[0164] (result) Hematoxylin-eosin (HE) staining revealed that the epithelial cell layer of the amniotic membrane remaining on the filter was not digested, and that many epithelial cells were present within the epithelial cell layer. In addition, the extracellular matrix layer of the amniotic membrane remaining on the filter was digested, and no amniotic MSCs were identified on the filter. This indicates that by using collagenase and dispase, which target the extracellular matrix layer of the amniotic membrane and not the epithelial cell layer of the amniotic membrane, a filtrate containing almost no epithelial cells was recovered.
[0165] The number of cells obtained from the amniotic tissue was 1.5 × 10 per gram of tissue weight as a result of cell counting using Turk's staining. 6 It was confirmed that it was an individual.
[0166] Flow cytometry revealed that the cell population, including the cells recovered from the filtrate, was CD90 positive, indicating that the cells recovered from the filtrate were mesenchymal stem cells.
[0167] (Step 3-3: Preculture 1) A portion of the cell population obtained from the enzyme treatment of the amniotic membrane was 2 The cells were seeded in a plastic culture vessel and cultured for 3 days in αMEM containing 10% FBS and 1× Antibiotic-Antimycotic.
[0168] (Step 3-4: Preculture 2) The adherent cells obtained in step 3-3 were treated with TrypLE Select (1x) (Thermo Fisher Scientific) to detach the cells from the plastic culture vessel. The obtained cell suspension was centrifuged and the supernatant was removed. The obtained cell pellet was suspended in αMEM containing 10% FBS and 1x Antibiotic-Antimycotic. A portion of the obtained cell suspension was transferred to a 150cm 2 The cells were seeded in a plastic culture vessel and cultured for 7 days in αMEM containing 10% FBS and 1× Antibiotic-Antimycotic.
[0169] (Step 3-5: Preculture 3) (method) The adherent cells obtained in step 3-4 were treated with TrypLE Select (1x) (Thermo Fisher Scientific) to detach the cells from the plastic culture vessel. The obtained cell suspension was centrifuged and the supernatant was removed. The obtained cell pellet was suspended in αMEM containing 10% FBS and 1x Antibiotic-Antimycotic. A portion of the obtained cell suspension was transferred to a 150cm 2 The cells were seeded in a plastic culture vessel and cultured for 8 days in αMEM containing 10% FBS and 1x Antibiotic-Antimycotic. The cells obtained by this preculture are called preculture 3 cells. Preculture 3 cells were used in the following tests.
[0170] (result) After 8 days of culture, preculture 3 cells were 6.7 × 10 3 pieces / cm 2 In this case, the specific growth rate of the precultured 3 cells was 0.11 (1 / day).
[0171] (Step 3-6: Stimulation of amniotic membrane MSCs by freezing and thawing) (method) The adherent cells (pre-cultured 3 cells) obtained in step 3-5 were treated with TrypLE Select (1x) to detach the cells from the plastic culture vessel. The resulting cell suspension was centrifuged and the supernatant was removed. The resulting cell pellet was diluted to 2.0x10 in RPMI1640 medium containing 0.5% (w / v) human serum albumin (HSA). 6The cells were suspended at a concentration of 12 cells / mL. A cryopreservation solution containing 12% (w / v) HES, 10% (w / v) DMSO, and 8% (w / v) HSA was prepared. The cell suspension and the cryopreservation solution were mixed in equal amounts on ice and dispensed into cryotubes. Using a programmable freezer, the cryotubes were cooled to -40°C at a rate of -2°C / min to -1°C / min, then cooled to -90°C at a rate of -10°C / min, and then frozen and stored in a cryotube at -150°C for 30 days. The cryotubes that had been frozen and stored were immersed in a 37°C incubator and rapidly thawed. A portion of the thawed cell suspension was collected and stained with trypan blue, and the number, viability, and size of the cells were measured using a hemocytometer.
[0172] (result) The diameter of the amniotic membrane MSCs in a suspended state immediately after the freeze-thaw process was 22.2±5.0 μm (ie, average diameter 22.2 μm).
[0173] (Step 3-7: Main culture 1) (method) The thawed cell suspension obtained in step 3-6 was centrifuged and the supernatant was removed. The obtained cell pellet was suspended in αMEM containing 10% FBS and 1× Antibiotic-Antimycotic. A portion of the obtained cell suspension was poured into a 150 cm 2 The cells were seeded in a plastic culture vessel and cultured in αMEM containing 10% FBS and 1x Antibiotic-Antimycotic for 7 days. The cells (a cell population containing amnion MSCs with a high specific proliferation rate, i.e., a cell population containing amnion MSCs with relatively high proliferation ability) were collected by TrypLE Select (1x) treatment and centrifugation. The cells obtained by this process are referred to as main culture 1 cells.
[0174] (result) The number of cells in the main culture obtained in step 3-7 was 2.2 x 10 6 This result indicates that 2.1 × 10 3 (pcs / cm 2It can be seen that amniotic membrane MSCs (100 / day) were obtained. The specific proliferation rate of the obtained cells was 0.21 (1 / day). Furthermore, the obtained amniotic membrane MSCs were viable cells suitable for cell formulation. These results demonstrate that it is possible to rapidly prepare and produce large quantities of amniotic membrane MSCs required for cell formulation.
[0175] (Step 3-8: Main culture 2) (method) A portion of the main culture 1 cells obtained in step 3-7 was seeded at a density of 6.0 × 10 3 pieces / cm 2 So, 150cm 2 The cells were seeded in a plastic culture vessel and cultured in αMEM containing 10% FBS and 1× Antibiotic-Antimycotic for 5 days. The cells (a cell population containing amnion MSCs with a high specific proliferation rate, i.e., a cell population containing amnion MSCs with relatively high proliferation ability) were collected by TrypLE Select (1×) treatment and centrifugation. The cells obtained by this process are referred to as passage 1 cells.
[0176] (result) The number of passage 1 cells obtained in steps 3-8 was 4.6 x 10 6 This result indicates that 4.4 × 10 3 (pcs / cm 2 It can be seen that amniotic membrane MSCs (100 / day) were obtained. The specific proliferation rate of the obtained cells was 0.32 (1 / day). Furthermore, the obtained amniotic membrane MSCs were viable cells suitable for cell formulation. These results demonstrate that it is possible to rapidly prepare and produce large quantities of amniotic membrane MSCs required for cell formulation.
[0177] (Step 3-9: Main culture 3) (method) A portion of the passage 1 cells obtained in step 3-8 was seeded at a density of 2.5 × 10 3 pieces / cm 2 So, 150cm 2The cells were seeded in a plastic culture vessel and cultured in αMEM containing 10% FBS and 1× Antibiotic-Antimycotic for 6 days. The cells (a cell population containing amnion MSCs with a high specific proliferation rate, i.e., a cell population containing amnion MSCs with relatively high proliferation ability) were collected by TrypLE Select (1×) treatment and centrifugation. The cells obtained by this process are referred to as passage 2 cells. Using the Cellular Senescence Detection Kit (SA-β-Gal Staining) (Cell Biolabs), a cellular senescence assay (cell staining) was performed on preculture 3 cells and passage 2 cells. In addition, a portion of the main culture 1 cells, passage 1 cells, and passage 2 cells was collected and stained with a labeled antibody at 4°C for 15 minutes, after which propidium iodide or 7-AAD (7-Amino-Actinomycin D) was added to remove dead cells, and surface antigens were analyzed using a flow cytometer (FACSCanto: BD). The labeled antibodies used were anti-CD90-FITC antibody (BD), anti-CD105-FITC antibody (Ancell), anti-CD73-PE antibody (BD), anti-CD106-PE antibody (Miltenyi Biotec), anti-CD324-PE antibody (BD), anti-CD326-FITC antibody (BD), anti-CD45-FITC antibody (BD), anti-CD34-PE antibody (BD) and anti-HLA-DR-FITC antibody (BD). The ratio of mesenchymal stem cells positive for specific expression markers (CD106, CD90) in the cell population was calculated by the following steps (1) to (3). (1) The measurement results were plotted in a histogram with the cell number on the vertical axis and the fluorescence intensity of the dye labeled to the antibody on the horizontal axis. (2) The fluorescence intensity at which the cell population with stronger fluorescence intensity accounted for 0.1 to 1.0% of the total cells measured using the isotype control antibody was determined. (3) The percentage of cells with a higher fluorescence intensity than that determined in (2) above was calculated from the total cells measured with antibodies against specific expression markers (CD106, CD90).
[0178] (result) The number of passage 2 cells obtained in steps 3-9 was 3.9 x 10 6 This result indicates that the number of cells per batch of culture was 3.7 × 10 3 (pcs / cm 2 It can be seen that amniotic membrane MSCs (100 / day) were obtained. The specific proliferation rate of the obtained cells was 0.39 (1 / day). Furthermore, the obtained amniotic membrane MSCs were viable cells suitable for cell formulation. These results demonstrate that it is possible to rapidly prepare and produce large quantities of amniotic membrane MSCs required for cell formulation.
[0179] In order to examine the number of possible passages, the passage 2 cells obtained in step 3-9 were further passaged and cultured, and passage 10 cells (cells that had been passaged 10 times) could be obtained. This shows that the cells obtained after the freeze-thaw treatment can be passaged at least 10 times.
[0180] A cellular senescence assay (cell staining) of amniotic MSCs was performed using the senescence marker senescence associated β-galactosidase (SA-β-Gal) as an indicator. As a result, pre-cultured 3 cells were SA-β-Gal positive, whereas passage 2 cells were SA-β-Gal negative. The proportion of SA-β-Gal negative mesenchymal stem cells in the cell population containing pre-cultured 3 cells was 2.9±2.3% (average proportion: 2.9%). On the other hand, the proportion of SA-β-Gal negative mesenchymal stem cells in the cell population containing passage 2 cells was 94.3±3.9% (average proportion: 94.3%).
[0181] As a result of flow cytometry, CD90, CD105 and CD73 were all positive in the main culture 1 cells, the passage 1 cells and the passage 2 cells, and CD106, CD324, CD326, CD45, CD34 and HLA-DR were all negative. In the cell population containing the main culture 1 cells, the passage 1 cells or the passage 2 cells, the ratio of mesenchymal stem cells positive for CD106 was 0.0%. In the cell population containing the main culture 1 cells, the passage 1 cells or the passage 2 cells, the ratio of mesenchymal stem cells positive for CD90 was 95%, 99% and 97%, respectively. These indicate that the main culture 1 cells, the passage 1 cells and the passage 2 cells are amniotic membrane MSCs that contain almost no epithelial cells, blood cells or vascular endothelial cells. The obtained amniotic membrane MSCs were viable cells suitable for cell formulation.
[0182] Example 4 A comparative analysis of gene expression in amniotic membrane MSCs with different specific proliferation rates was carried out by the following steps 4-1 to 4-3.
[0183] (Step 4-1: Extraction of total RNA) (method) Adherent pre-cultured 3 cells (specific growth rate: 0.11 (1 / day)) obtained in step 3-5 of Example 3 and adherent passage 2 cells (specific growth rate: 0.39 (1 / day)) obtained in step 3-9 of Example 3 were detached from the plastic culture vessel using a cell scraper (manufactured by Corning) and collected by centrifugation. RNAlater (manufactured by Thermo Fisher Scientific) was added to the obtained cell pellet to stably store RNA, and then total RNA was extracted and purified using RNeasy Plus Mini kit (manufactured by QIAGEN).
[0184] (result) As a result of electrophoretic pattern analysis using the LabChip kit and Agilent 2100 Bioanalyzer, two clear ribosomal RNA (18SrRNA, 28SrRNA) peaks were detected in both RNA samples. In addition, as a result of quantification using a spectrophotometer NanoDrop (Thermo Fisher Scientific), the A260 / A280 ratio of both RNA samples was between 1.8 and 2.1. From the above, it was confirmed that both RNA samples were of an appropriate purity for array analysis samples.
[0185] (Step 4-2: Acquisition of microarray data) (method) cDNA was synthesized from 100 ng of total RNA by reverse transcription, and then the cDNA was transcribed to cRNA by in vitro transcription and biotin-labeled (using the 3'IVT PLUS Reagent Kit). 10.0 μg of labeled cRNA was added to the hybridization buffer, and hybridization was performed on the Human GeneGenome U133A 2.0 Array (Affymetrix) for 16 hours. After washing and phycoerythrin staining with the GeneChip Fluidics Station 450 (Affymetrix), scanning was performed with the GeneChip Scanner 3000 7G (Affymetrix), image analysis was performed with AGCC (Affymetrix GeneChip Command Console Software) (Affymetrix), and quantification was performed using the Affymetrix Expression Console (Affymetrix).
[0186] (result) Data analyzed using the Affymetrix Expression Console showed that the signal (3' / 5') ratios of the housekeeping gene GAPDH in each sample were 0.98 and 1.04, respectively (ideal value of 3 or less), confirming that there was no problem with the quality of the obtained cRNA.
[0187] (Step 4-3: Analysis of microarray data) (method) The numerical data files for the two arrays were analyzed comparatively using the analysis software GeneSpring GX (Agilent Technologies). The normalized value for the passage 2 cell sample was divided by the normalized value for the control sample of pre-cultured 3 cells, and probes with a quotient of 2 or more were selected to search for genes whose expression changed by 2-fold or more (genes showing a fold change value of 2-fold or more).
[0188] (result) The results of comparing gene expression of metallothionein isoforms between passage 2 cells and preculture 3 cells are shown in Table 4.
[0189] [Table 4]
[0190] From Table 4, it was found that compared with preculture 3 cells, passage 2 cells showed more than twice the fold change values for metallothionein-1E (MT1E), metallothionein-1F (MT1F), metallothionein-1G (MT1G), metallothionein-1H (MT1H), metallothionein-1X (MT1X), and metallothionein-2A (MT2A). From the above, it was revealed that passage 2 cells highly expressed these metallothionein family genes.
[0191] Example 5 A composition containing amniotic membrane MSCs with a high specific proliferation rate was prepared, and the composition was cryopreserved and thawed, after which the viability of the cells in the composition was measured.
[0192] (method) 8.0 × 10 amniotic membrane MSCs (passage 2 cells) obtained in step 3-9 of Example 3 6A composition consisting of 1 mL of RPMI1640 medium containing 100 μg of erythrocytes, 20 mg of dextran, 52 mg of DMSO, and 40 mg of human serum albumin was prepared. The composition was sealed in a cryotube and stored in a frozen state at -150°C for 7 days. The frozen composition was rapidly thawed in a 37°C incubator and then allowed to stand at 25°C (room temperature) or 37°C (body temperature) for 1 or 2 hours. A portion of the obtained composition was collected and stained with trypan blue, and the cell viability was measured using a hemocytometer.
[0193] (result) The cell viability of the composition immediately after thawing was 96.3±1.2%. The cell viability of the composition left standing at 25°C for 1 or 2 hours was 94.7±1.5% and 93.0±1.0%, respectively. The cell viability of the composition left standing at 37°C for 1 or 2 hours was 92.7±3.1% and 90.3±2.9%, respectively. From the above, it was confirmed that a high cell viability of 90% or more could be maintained for at least 2 hours at both 25°C and 37°C.
[0194] Example 6 (Cell formulation and administration) A portion of the amniotic MSCs (amniotic MSCs with a high specific proliferation rate, i.e., amniotic MSCs with relatively high proliferation ability) obtained in steps 2-8 of Example 2 or steps 3-9 of Example 3 was used to prepare a pharmaceutical composition. 8 A pharmaceutical composition (cell preparation) consisting of 25 mL of RPMI1640 medium containing 0.50 g of HES or dextran, 1.3 g of DMSO, and 1.0 g of human serum albumin was prepared. The pharmaceutical composition was sealed in a freezing bag and stored in a frozen state. When using the pharmaceutical composition, first, the frozen pharmaceutical composition is rapidly thawed at 37° C., and then the thawed pharmaceutical composition is diluted with physiological saline. Next, the pharmaceutical composition can be administered to a patient by intravenous injection, intravenous drip injection, or local direct injection while gently mixing to uniformly disperse the cells in the diluted composition.
Claims
1. A method for producing a cell population comprising mesenchymal stem cells, comprising: a selection step of suspending a cell population containing mesenchymal stem cells with different proliferation capabilities in a freezing storage solution, freezing the resulting suspension at a temperature of -30°C or lower at a freezing rate of 2°C / min or less, and then maintaining the frozen state at a temperature of -30°C or lower for 30 days or more, and then thawing the suspension to select mesenchymal stem cells; A step of culturing and subculturing the cell population containing mesenchymal stem cells obtained in the selection step. Including, The suspension contains 4% to 10% by weight of dimethyl sulfoxide, 2% to 13% by weight of hydroxyethyl starch, and 3% to 9% by weight of albumin; In the mesenchymal stem cells that have been subjected to the steps of culturing and subculturing, the expression level of metallothionein family genes is increased compared to before the freezing, The mesenchymal stem cells that have undergone the culturing and subculturing steps are characterized in that they are CD106 negative. A method for producing the cell population.
2. The method for producing a cell population according to claim 1 , wherein the frozen state is maintained at a temperature of −130° C. or lower.
3. The method for producing a cell population according to claim 1 or 2, further comprising a cell population obtaining step of obtaining a cell population containing mesenchymal stem cells with different proliferation abilities by enzymatically treating fetal appendages in vitro.
4. The method for producing a cell population according to claim 3 , further comprising a step of culturing the cell population obtained in the cell population obtaining step.
5. The method for producing a cell population according to claim 1 , wherein the metallothionein family gene is at least one selected from the group consisting of MT1E, MT1F, MT1G, MT1H, MT1X and MT2A.
6. The method for producing a cell population according to any one of claims 1 to 5, wherein the selected mesenchymal stem cells are SA-β-Gal negative.
7. The method for producing a cell population according to claim 6, wherein the average ratio of SA-β-Gal-negative mesenchymal stem cells in the cell population is 90% or more.
8. The method for producing a cell population according to any one of claims 1 to 7, wherein the selected mesenchymal stem cells are CD105 positive, CD73 positive, CD90 positive, CD45 negative, CD34 negative, CD11b negative, CD79alpha negative, and HLA-DR negative.
9. The method for producing a cell population according to claim 1 , wherein the specific proliferation rate of the selected mesenchymal stem cells is 0.30 (1 / day) or more.
Citation Information
Patent Citations
Use of CD106 as differentiation potency marker of mesenchymal stem cell
JP2008220334A
Method for identifying and culturing pluripotent mesenchymal stem cells with high proliferative capacity
JP2014501110A
Method for producing sheet-like cell culture
JP2015015963A
Production method and cryopreservation method of amnion mesenchymal cell composition, and therapeutic agent
JP2015061520A
Method for preparing amniotic mesenchymal stem cell, and isolated amniotic mesenchymal stem cell mass
WO2013077428A1
